Books by Subject

Pharmacology

  • Clinical Drug Information
  • v. 1-, 2011- Springer
  • 2012 Wiley
    Alex Avdeef.
    Introduction Transport model pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability -- Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier.
  • AccessMedicine
    Toy, Eugene C.
    Clinical cases selected from the LANGE Case Files series, edited by Eugene C. Toy, MD.
  • 2012 CRCnetBASE
    Shein-Chung Chow, Mark Chang.
    Protocol amendment -- Adaptive randomization -- Adaptive hypotheses -- Adaptive dose-escalation trials -- Adaptive group sequential design -- Statistical tests for adaptive seamless designs -- Adaptive sample size adjustment -- Two-stage adaptive design -- Adaptive treatment switching -- Bayesian approach -- Biomarker adaptive trials -- Target clinical trials -- Sample size and power estimation -- Clinical trial simulation -- Regulatory perspectives : a review of FDA draft guidance.
  • 2006 Springer
    edited by Dianne M. Perez.
  • 2013 Springer
    edited by Nikhil C. Munshi, Kenneth C. Anderson.
    Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
  • 2013 Springer
    edited by Nikhil C. Munshi, Kenneth C. Anderson.
    Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
  • 2014 Springer
    Esen Özkaya, Kurtuluş Didem Yazganoğlu.
    This book describes adverse cutaneous drug reactions as among the most frequent events in patients receiving drug therapy. Cardiovascular drugs are an important group as there are a greater number of indications for the use of new drugs and their prescription continues to increase. The exact incidence of cutaneous side effects from cardiovascular drugs is difficult to estimate due to sporadic reporting. Moreover, a reliable connection between a certain drug and a certain type of reaction can only rarely be made, aside from the well-known angioedema/urticaria from angiotensin-converting enzyme inhibitors, lichen planus/lichenoid reaction from beta adrenergic blockers, and photosensitivity from thiazid diuretics. These reactions can extend to rare but life-threatening conditions such as erythroderma, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug hypersensitivity syndrome. Adverse Cutaneous Drug Reactions To Cardiovascular Drugs reviews the reported types of reactions to cardiovascular drugs. Each is discussed according to drug class and the type of dermatologic reaction with special emphasize on cross-reactions and the role of patch testing in diagnosis. A total of 116 images are included featuring clinical appearance of common adverse cutaneous drug reactions and diagnostic procedures such as patch and photopatch testing with the suspected drugs. Complementary tables may allow to scan the most common cutaneous reactions and the related cardiovascular drugs along with the possible cross reactions at first glance. It will thus be of considerable importance to all dermatologists and medical professionals who manage the skin, while being an important reference resource for cardiologists in terms of identifying potential adverse reactions to the drugs they prescribe.
  • 2010 Springer
    Jack Uetrecht, editor.
    Pt. 1. Target organ toxicity. -- Drug-induced liver injury / Michael Holt, Cynthia Ju.-- Drug herpersensitivity reactions involving skin / Oliver Hausmann, Benno Schnyder, Werner J. Pichler.-- Adverse drug reactions affecting blood cells / Richard H. Aster.-- Molecular mechanisms of adverse drug reactions in cardiac tissue / Reza Tabrizchi.-- Mechanisms of drug-induced nephrotoxicity / Thomas D. Nolin, Jonathan Himmelfarb.-- Receptor- and reactive intermediate-mediated mechanisms of teratogenesis / Peter G. Wells, Crystal J.J. Lee, Gordon P. McCallum, Julia Perstin, Patricia A. Harper.-- Pt. II. Mediators/Biochemical pathways.-- Role of reactive metabolites in drug-induced hepatotoxicity / A.M. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith, B. K. Park.-- Role of cytokines in the mechanism of adverse drug reactions / Mary Jane Masson, Lindsay A. Collins, Lance R. Poh.-- Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity / Ian M. Copple, Christopher E. Goldring, Neil R. Kitteringham, B. Kevin Park.-- Signal transduction pathways involved in drug-induced liver injury / Derick Han, Mie Shinohara, Maria D. Ybanez, Behnam Saberi, Neil Kaplowitz.-- Mictrochondrial involvement in drug-induced liver injury / Dominique Pessayre, Abdellah Mansouri, Alain Berson, Bernard Fromenty.-- Pt. III. Examples/Models.-- Mechanisms of acetaminophen-induced liver necrosis / Jack A. Hinson, Dean W. Roberts, Laura P. James.-- Drug-induced liver injury in humans: the case of Ximelagtran / M. Keisu, T.B. Andersson.-- Troglitazone / Tsuyoshi Yokoi.-- Neviropine hypersensitivity / M. Popovic, J.M. Shenton, J. Chen, A. Baban, T. Tharmanathan, B. Mannargudi, D. Abdulla, J.P. Uetrecht.-- Mechanisms of adverse drug reactions to biologics / Janet B. Clarke.-- Pt. IV. Risk factors/Screening drug candidates.-- Pharmacogenetics of idiosyncratic adverse drug reactions / Munir Pirmohamed.-- Danger hypothesis applied to idiosyncratic drug reactions / Jinze Li, Jack P. Uetrecht.-- Approaches for minimizing metabolic activation of new drug candidates in drug discovery / Sanjeev Kumar, Kaushik Mitra, Kelem Kassahun, Thomas A. Baillie.
  • 2014 ScienceDirect
    volume editors, Edith V. Sullivan and Adolf Pfefferbaum.
    "Alcohol is the most widely used drug in the world, yet alcoholism remains a serious addiction affecting nearly 20 million Americans. Our current understanding of alcohol's effect on brain structure and related functional damage is being revolutionized by genetic research, basic neuroscience, brain imaging science, and systematic study of cognitive, sensory, and motor abilities. Volume 125 of the Handbook of Clinical Neurology is a comprehensive, in-depth treatise of studies on alcohol and the brain covering the basic understanding of alcohol's effect on the central nervous system, the diagnosis and treatment of alcoholism, and prospect for recovery. The chapters within will be of interest to clinical neurologists, neuropsychologists, and researchers in all facets and levels of the neuroscience of alcohol and alcoholism"--Publisher's description.
  • 2014 Springer
    edited by Antonino Gullo.
    The APICE 2013 yearbook examines recent advances in various aspects of critical care medicine and highlights the importance of effective communication among researchers, scientists, and clinicians. Among the many topics addressed are trauma care organization, the management of patients with cardiovascular, kidney, and lung disorders, issues relating to severe infections and sepsis, and the humanization of end of life care. The overriding goal of the book is to provide guidance and stimulate further thought on how professional performance in critical care medicine can be improved. Triple B translational research, from the bench to the bedside and back again (via the translation of clinical observations into new research questions), will play a major role in this context, and is particularly discussed in the chapter about sepsis and organ dysfunction. There is no doubt that the transfer of far-reaching and dynamic developments in molecular and cellular biology into clinical practice will be a key component in delivering the care required by individual patients.
  • 2011 Springer
    Antonino Gullo (ed.).
    pt. I. Continuing medical education -- 1. Can I Think what I Read? / Philip D. Lumb -- pt. II. Clinical pharmacology -- 2. Pharmacological Manipulation in ICU / Daniel De Backer, Katia Donadello and Sabino Scolletta -- pt. III. Kidney -- 3. Renal Injury / Vladimir Gašparović, Ivan Gornik -- pt. IV. Ventilation: adult and paediatric -- 4. Respiratory Mechanics: Principles, Utility and Advances / Alysson R. Carvalho, Walter A. Zin -- 5. Capnometry/capnography in Prehospital Cardiopulmonary Resuscitation / Štefek Grmec, Katia Lah and Štefan Mally -- 6. Weaning from Mechanical Ventilation / Irene Cortés Puch, Andrés Esteban -- 7. Ventilatory Strategies in Acute Lung Injury / Edoardo Calderini, Sara Sher and Eleonora Allegritti -- 8. Mechanical Ventilation Beyond the PICU / Giancarlo Ottonello, Alessia Franceschi -- pt. V. Cardiovascular monitoring 9. The Nexfin Monitor--A Totally Non-Invasive Cardiac Output Monitor / Azriel Perel, Wilbert Wesselink and Jos Settels -- 10. Doppler Echocardiography in ICU Patients: Does It Improve Outcome? / Jan Poelaert -- pt. VI. Management of cardiac arrest -- 11. Mild Therapeutic Hypothermia after Cardiac Arrest / Tommaso Pellis, Vincenzo Mione and Willy P. Mercante -- 12. Nasopharyngeal Cooling During Cardiopulmonary Resuscitation / Francesco Fumagalli, Giuseppe Ristagno -- 13. Amplitude Spectrum Area as a Predictor of Successful Defibrillation / Giuseppe Ristagno, Yongqin Li, Antonino Gullo and Joe Bisera -- pt. VII. Advances in experimental and clinical research -- 14. Physiopathology and Severity of Post-Resuscitation Myocardial Dysfunction: Effects of Sodium-Hydrogen Exchanger Isoform-1 (NHE-1) Inhibitors and Erythropoietin / Raúl J. Gazmuri, Iyad M. Ayoub and Jeejabai Radhakrishnan -- 15. Experimental Treatment for Preservation of Mechanically Competent Cardiac Activity Following Cardiac Arrest / Iyad M. Ayoub, Jeejabai Radhakrishnan and Raúl J. Gazmuri -- 16. Erythropoietin Facilitates Return of Spontaneous Circulation and Survival in Victims of Out-of-Hospital Cardiac Arrest / Štefek Grmec, Matej Strand and Raúl J. Gazmuri -- pt. VIII. Infections, sepsis and organ dysfunctions -- 17. Pathophysiology of Resistance amongst Aerobic Gram-negative Bacilli in Particular Acinetobacter Species / Nia Taylor, Luciano Silvestri and Hendrick K.F. Van Saene -- 18. What Have We Learned from the Surviving Sepsis Campaign? / Jean-Louis Vincent, Katia Donadello and Leonardo Gottin -- 19. Source Control / Gabriele Sganga, Valerio Cozza -- 20. Immunoglobulins in Sepsis / Giorgio Berlot, Claudio M. Vassallo and Nicola Busetto -- pt. IX. Perioperative medicine -- 22. Perioperative Medicine--An Introduction / Antonino Gullo, Chiara M. Celestre, Annalaura Paratore and Fortunato Stimoli -- 23. Neuraxial Analgesia for Caesarean and Vaginal Delivery and Childhood Learning Disabilities / Juraj Sprung, Randall Flick and David Warner -- 24. Off-label Drugs in Perioperative Medicine: Clonidine / Cesare Gregoretti, Paolo Pelosi -- pt. X. Spinal cord stimulation -- 25. Cost Effectiveness of Spinal Cord Stimulation in the Management of Severe Angina / Mats Börjesson, Clas Mannheimer -- pt. XI. Neurotrauma -- 26. Clinical Assessment and Diagnostic Procedures in Neurotrauma / Marco Zanello, Matteo Vincenzi and Marco Bandini -- pt. XII. Disaster medicine -- 27. Disaster Preparedness / Francesco Della Corte, Pier Luigi Ingrassia -- 28. Medical Emergency Response in Toxicological Mass Casualty / Pier Luigi Ingrassia, Luca Ragazzoni and Francesco Della Corte -- pt. XIII. Quality of care -- 29. Telemedicine to Improve Care in the Critically Ill / Gastón Murias, Bernat Sales Lluis Blanch -- 30. Professionalism, Quality of Care and Pay-for-Performance Services / Antonino Gullo, Cristina Santonocito, Paolo Murabito and Marinella Astuto.
  • 2013 Wiley
    edited by János Fischer, C. Robin Ganellin, David P. Rotella.
    General Aspects. Pioneer and Analogue Drugs / Janos Fischer, C Robin Ganellin, David P Rotella -- Competition in the Pharmaceutical Drug Development / Christian Tyrchan, Fabrizio Giordanetto -- Metabolic Stability and Analogue-Based Drug Discovery / Amit S Kalgutkar, Antonia F Stepan -- Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / A Ganesan -- Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Joseph A Jakubowski, Atsuhiro Sugidachi -- Selective Estrogen Receptor Modulators / Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / Kazumi Kondo, Hidenori Ogawa -- The Development of Cysteinyl Leukotriene Receptor Antagonists / Peter R Bernstein -- Case Studies. The Discovery of Dabigatran Etexilate / Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- The Discovery of Citalopram and Its Refinement to Escitalopram / Klaus P Bogeso, Connie Sanchez -- Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Helmut Buschmann -- Novel Taxanes: Cabazitaxel Case Study / Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- A New-Generation Uric Acid Production Inhibitor: Febuxostat / Ken Okamoto, Shiro Kondo, Takeshi Nishino.
  • 2011
    edited by Alex S. Evers, Mervyn Maze, Evan D. Kharasch.
    Status: Not Checked OutLane Catalog Record
    "In recent years our understanding of molecular mechanisms of drug action and interindividual variability in drug response has grown enormously. Meanwhile, the practice of anesthesiology has expanded to the preoperative environment and numerous locations outside the OR. Anesthetic Pharmacology: Basic Principles and Clinical Practice, second edition, is an outstanding therapeutic resource in anesthesia and critical care: Section 1 introduces the principles of drug action, Section 2 presents the molecular, cellular and integrated physiology of the target organ/functional system and Section 3 reviews the pharmacology and toxicology of anesthetic drugs. The new Section 4, Therapeutics of Clinical Practice, provides integrated and comparative pharmacology and the practical application of drugs in daily clinical practice. Edited by three highly acclaimed academic anesthetic pharmacologists, with contributions from an international team of experts, and illustrated in full colour, this is a sophisticated, user-friendly resource for all practitioners providing care in the perioperative period"--Provided by publisher.
  • 2014 CRCnetBASE
    edited by Taylor C. Wallace, M. Monica Giusti.
  • 2014 ScienceDirect
    edited by Atta-ur-Rahman, FRS, and Muhammad Iqbal Choudhary.
    The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.
  • 2012 Springer
    Thomas J. Dougherty, Michael J. Pucci, editors.
  • 2012 Springer
    edited by Anthony R.M. Coates.
    Introduction to antibiotic resistance/ Richard Bax, David Griffin -- The origins of antibiotic resistance/ Gerard D. Wright -- Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends/ Stephen Hawser -- Current and future challenges in the development of antimicrobial agents/ Robert P. Rennie -- The role of the outer membrane of gram-negative bacteria in antibiotic resistance: Ajax' shield or Achilles' heel?/ Malcolm G.P. Page -- Prevention of drug resistance by combined drug treatment of tuberculosis/ Denis A. Mitchison -- Nonmultiplying bacteria are profoundly tolerant to antibiotics / Yanmin Hu, Anthony Coates -- Persister cells: molecular mechanisms related to antibiotic tolerance / Kim Lewis -- Antimicrobial textiles / J. Vaun McArthur, R.C. Tuckfield, C. Baker-Austin -- Efflux: how bacteria use pumps to control their microenvironment / E. David G. McIntosh -- Antibiotics in phase II and III clinical trials / Anthony R.M. Coates, Gerry Halls.
  • 2015
    This brief provides an overview of antibiotic resistance, including a summary of its current impact, the factors that contribute to its spread, and the policy recommendations put in place by federal and global public health agencies. It also reviews the debate around the regulation of antibiotic use in agriculture and examines new developments in policy and research associated with multidrug-resistant bacterial diseases and their underlying causes.
  • 2015 Ovid
    Daniel Amsterdam, Phd, ABMM, FAAAS, FIDSA, Professor, Department of Microbiology & Immunology, Medicine, and Pathology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Chief of Service, Department of Laboratory Medicine, Erie County MEdical Center, Buffalo, New York.
    The breakpoint / Matthew A. Wikler, Franklin R. Cockerill III, and Paul G. Ambrose -- Antimicrobial susceptibility on solid media / John D. Turnidge and Jan M. Bell -- Susceptibility testing of antimicrobials in liquid media / Daniel Amsterdam -- Antimicrobial susceptibility testing of anaerobic bacteria / Anilrudh A. Venugopal and David W. Hecht -- Antimycobacterial agents : in vitro susceptibility testing and mechanisms of action and resistance / Clark B. Inderlied and Edward Desmond -- Antifungal drugs : mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids / George R. Thompson III and Thomas F. Patterson -- Antimicrobial susceptibility testing for some atypical microorganisms (Chlamydia, Mycoplasma, Rickettsia, Ehrlichia, Coxiella, and Spirochetes) / Jean-Marc Rolain -- Applications, significance of, and methods for the measurement of antimicrobial concentrations in human body fluids / Shelly Latte, Emilia Mia Sordillo, and Stephen C. Edberg -- Molecular methods for the detection of antibacterial resistance genes : rationale and application / Kristin Hegstad, Törjan Samuelsen, Joachim Hegstad, and Arnfinn Sundsfjord -- Molecular mechanisms of action for antimicrobial agents : general principles and mechanisms for selected classes of antibiotics / Charles William Stratton -- Antiviral agents for HIV, hepatitis, cytomegalovirus, and influenza : susceptibility testing methods, modes of action, and resistance / Daniel Amsterdam -- Disinfectants and antiseptics : modes of action, mechanisms of resistance, and testing regimens / Daniel Amsterdam and Barbara E. Ostrov -- Evaluation of antimicrobials in experimental animal infections / D.A. Andes, Alexander J. Lepak, Niels Frimodt-Möller -- Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans / David M. Bamberger, John W. Foxworth, Michael Alan Kallenberger, Brian S. Pepito, and Dale N. Gerding -- Appendix : antiinfective resistance resource guide / Daniel Amsterdam.
  • 2010 Springer
    David M. Shlaes.
  • 2013 Springer Protocols
    edited by Laurent Ducry.
    Antibody-drug conjugate (ADC) clinical pipeline : a review / Ingrid Sassoon and Veronique Blanc -- Antibody-drug conjugate target selection : critical factors / Neil H. Bander -- Selecting an optimal antibody for antibody-drug conjugate therapy : internalization and intracellular localization / Jay Harper ... [et al.] -- Antibody-drug conjugate payloads / Jan Anderl ... [et al.] -- Linker technologies for antibody-drug conjugates / Birte Nolting -- In vivo testing of drug-linker stability / Pierre-Yves Abecassis and Celine Amara -- Pharmacokinetics and ADME characterizations of antibody-drug conjugates / Kedan Lin, Jay Tibbitts, and Ben-Quan Shen -- Safe handling of cytotoxic compounds in a biopharmaceutical environment / Miriam I. Hensgen and Bernhard Stump -- Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting / James E. Stefano ... [et al.] -- Protocols for lysine conjugation / Marie-Priscille Brun and Laurence Gauzy-Lazo -- Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers / Sunil Bhakta, Helga Raab, and Jagath R. Junutula -- Enzymatic antibody modification by bacterial transglutaminase / Patrick Dennler, Roger Schibli, and Eliane Fischer -- Formulation development of antibody-drug conjugates / William J. Galush and Aditya A. Wakankar -- Conjugation process development and scale-up / Bernhard Stump and Jessica Steinmann -- Methods for conjugating antibodies to nanocarriers / Anil Wagh and Benedict Law -- Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy / Yan Chen -- Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography / Jun Ouyang -- Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS / Louisette Basa -- Determination of charge heterogeneity and level of unconjugated antibody by imaged cIEF / Joyce Lin and Alexandru C. Lazar -- Risk-based scientific approach for determination of extractables/leachables from biomanufacturing of antibody-drug conjugates (ADCs) / Weibing Ding.
  • 2015 Springer
    Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro, editors.
    This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
  • 2013 Springer
    Gail Lewis Phillips, editor.
    The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
  • 2012 CRCnetBASE
    edited by Gordon M. Cragg, David G.I. Kingston, and David J. Newman.
    "This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"-- Provided by publisher. "The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- Provided by publisher.
  • 2012 Ovid
    Finch, R. G.
    Pt. 1. General properties of antimicrobial agents -- Pt. 2. Resistance to antimicrobial agents -- Pt. 3. General principles of usage of antimicrobial agents -- Pt. 4. Therapeutic use of antimicrobial agents.
  • 2013 Wiley
    David A. Phoenix, Sarah R. Dennison, and Frederick Harris.
    Antimicrobial peptides: their history, evolution, and functional promiscuity -- Cationic antimicrobial peptides -- Anionic antimicrobial peptides -- Graphical techniques to visualize the amphiphilic structures of antimicrobial peptides -- Models for the membrane interactions of antimicrobial peptides -- Selectivity and toxicity of oncolytic antimicrobial peptides.
  • 2015 Wiley
    Daniel Lednicer.
    "Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"-- Provided by publisher.
  • 2012 Springer
    Paolo Gresele, Gustav V. R Born, Carlo Patrono, Clive P. Page, editors.
    Part 1. Pathophysiology. Platelets: Production, Morphology and Ultrastructure / Jonathan N. Thon and Joseph E. Italiano -- Platelet Receptors / Alexandre Kauskot and Marc F. Hoylaerts -- Platelet Signaling / Timothy J. Stalker, Debra K. Newman, Peisong Ma, Kenneth M. Wannemacher and Lawrence F. Brass -- Platelet Interaction with the Vessel Wall / Philip G. de Groot, Rolf T. Urbanus and Mark Roest -- Platelets in Atherosclerosis and Thrombosis / Christian Schulz and Steffen Massberg -- Part 2. Pharmacology. Aspirin and Other COX-1 Inhibitors / Carlo Patrono and Bianca Rocca -- Thienopyridines and Other ADP-Receptor Antagonists / Isabell Bernlochner and Dirk Sibbing -- Glycoprotein IIb/IIIa Antagonists / Karen M. Hook and Joel S. Bennett -- Targeting Phosphodiesterases in Anti-platelet Therapy / Matthew T. Rondina and Andrew S. Weyrich -- PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis / Sergio Leonardi and Richard C. Becker -- Thromboxane Receptors Antagonists and/or Synthase Inhibitors / Giovanni Davì, Francesca Santilli and Natale Vazzana -- Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V / Paolo Gresele and Stefania Momi -- Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets / Hans Deckmyn, Simon F. De Meyer, Katleen Broos and Karen Vanhoorelbeke -- Intracellular Signaling as a Potential Target for Antiplatelet Therapy / Patrick Andre -- Novel Targets for Platelet Inhibition / Kathleen Freson and Chris Van Geet -- Variability of Platelet Indices and Function: Acquired and Genetic Factors / Giovanni de Gaetano, Iolanda Santimone, Francesco Gianfagna, Licia Iacoviello and Chiara Cerletti -- Small RNAs as Potential Platelet Therapeutics / Leonard C. Edelstein and Paul F. Bray -- Pharmacological Modulation of the Inflammatory Actions of Platelets / Richard Amison, Clive Page and Simon Pitchford -- Part 3. Therapy. The Role of Laboratory Monitoring in Antiplatelet Therapy / Marco Cattaneo -- Antiplatelet Agents in Ischemic Heart Disease / Christopher H. May and A. Michael Lincoff -- Antiplatelet Therapy in Cerebrovascular Disorders / Ralph Weber, Johannes Brenck and Hans-Christoph Diener -- Antiplatelet Therapy in Peripheral Artery Disease / Francesco Violi, Stefania Basili, Jeffrey S. Berger and William R. Hiatt -- Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents / Tom Mead.
  • 2008 CRCnetBASE
    edited by Stanley T. Crooke.
    Mechanisms of antisense drug action, an introduction / Stanley T. Crooke ... [et al.] -- The RNase H mechanism / Walt Lima, Hongjiang Wu, and Stanley T. Crooke -- Small RNA silencing pathways / Alla Sigova and Phillip D. Zamore -- Splice switching oligonucleotides as potential therapeutics / Peter Sazani, Maria A. Graziewicz, and Ryszard Kole -- Basic principles of antisense drug discovery / Susan M. Freier and Andrew T. Watt -- The medicinal chemistry of oligonucleotides / Eric E. Swayze and Balkrishen Bhat -- Basic principles of the pharmacokinetics of antisense oligonucleotide drugs / Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary -- Routes and formulations for delivery of antisense oligonucleotides / Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary -- Liposomal formulations for nucleic acid delivery / Ian MacLachlan -- Pharmacological properties of 2'-O-methoxyethyl-modified oligonucleotides / C. Frank Bennett -- Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man / Richard S. Geary ... [et al.] -- Toxicologic properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man / Scott P. Henry ... [et al.] -- An overview of the clinical safety experience of first- and second-generation antisense oligonucleotides / T. Jesse Kwoh -- Manufacturing and analytical processes for 2'-O-(2-methoxyethyl)-modified oligonucleotides / Daniel C. Capaldi and Anthony N. Scozzari -- Utilizing chemistry to harness RNA interference pathways for therapeutics : chemically modified siRNAs and antagomirs / Muthiah Manoharan and Kallanthottathil G. Rajeev. Discovery and development of RNAi therapeutics / Antonin R. deFougerolles and John M. Maraganore -- Optimization of second-generation antisense drugs: going beyond generation 2.0 / Brett P. Monia ... [et al.] -- Modulating gene function with peptide nucleic acids (PNA) / Peter E. Nielsen -- Locked nucleic acid / Troels Koch and Henrik Ørum -- Morpholinos / Patrick L. Iversen -- Potential therapeutic applications of antisense oligonucleotides in ophthalmology / Lisa R. Grillone and Scott P. Henry -- Cardiovascular therapeutic applications / Rosanne M. Crooke, Brenda Baker, and Mark Wedel -- Developing antisense drugs for metabolic diseases: a novel therapeutic approach / Sanjay Bhanot -- Inflammatory diseases / Susan A. Gregory and James G. Karras -- Antisense oligonucleotides for the treatment of cancer / Boris A. Hadaschik and Martin E. Gleave -- Targeting neurological disorders with antisense oligonucleotides / Richard A. Smith and Timothy M. Miller -- Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for toll-like receptors / Jörg Vollmer and Arthur M. Krieg -- Aptamer opportunities and challenges / Charles Wilson.
  • 2013 Springer
    Evandro Fei Fang, Tzi Bun Ng, editors.
    The modern unhealthy diet and lifestyle in conjunction with pathogens, environmental carcinogens and multiple other risk factors increase humans' susceptibility to different diseases exemplified by elevated levels of cancers, cardiovascular and communicable diseases. Screening of potential drugs from medicinal plants and animals provides a promising strategy for the alleviation of the impact of these diseases. Components with potential medicinal applications include RIPs, RNases, lectins, protease inhibitors and numerous small compounds. These compounds have shown both preventive and therapeutic effects for humans. This book is a compilation of articles written by internationally renowned experts exploring the different uses of medicinal compounds in human therapeutics. Here we provide a comprehensive outlook on both qualitative and quantitative studies focusing on medicinal plants and animals, and establishing a link between laboratory research discovery and clinical applications.
  • 2013 Springer Protocols
    edited by Edwin Yunhao Gong.
    Part I Human immunodeficiency virus type 1 (HIV-1) -- Fluorescence-based high-throughput screening assay to identify HIV-1 inhibitors / Peggy Geluykens ... [et al.] -- Homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion / Liesbet Smeulders ... [et al.] -- Identification of HIV-1 reverse transcriptase inhibitors using a scintillation proximity assay / Bertrand Van Schoubroeck ... [et al.] -- Biochemical screening assays to identify HIV-1 integrase inhibitors / Marleen Clynhens ... [et al.] -- HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance / Peter Van den Eede ... [et al.] -- Part II Hepatitis viruses -- In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis / Rumin Zhang and William T. Windsor -- Novel hepatitis C virus NS5B polymerase assay of de novo initiated RNA synthesis directed from a heteropolymeric RNA template / Eric Ferrari and Hsueh-Cheng Huang -- Selecting and characterizing drug-resistant hepatitis C virus replicon / Inge Vliegen, Leen Delang, and Johan Neyts -- Cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors / Leen Vijgen ... [et al.] -- Expression and purification of hepatitis C virus protease from clinical samples / Liesbet van der Helm -- Surface plasmon resonance as a tool to select potent drug candidates for hepatitis C virus NS5B polymerase / Erna Cleiren, Benoit Devogelaere, and Katleen Fierens -- Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b / Diana Koletzki ... [et al.] -- Southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures / Dawei Cai ... [et al.] -- In vitro phenotyping of recombinant hepatitis B virus containing the polymerase/reverse transcriptase gene from clinical isolates / Yang Liu and Kathryn M. Kitrinos -- Part III Flaviviruses -- Cell-based antiviral assays for screening and profiling inhibitors against dengue virus / Edwin Yunhao Gong ... [et al.] -- Duplex real-time RT-PCR assay for profiling inhibitors of four dengue serotypes / Edwin Yunhao Gong ... [et al.] -- High-throughput screening using dengue virus reporter genomes / Wolfgang Fischl and Ralf Bartenschlager -- Fluorimetric and HPLC-based dengue virus protease assays using a FRET substrate / Christoph Nitsche and Christian D. Klein -- Expression and purification of dengue virus NS5 polymerase and development of a high-throughput enzymatic assay for screening inhibitors of dengue polymerase / Edwin Yunhao Gong ... [et al.] -- Detection and quantification of flavivirus NS5 methyl- transferase activities / Siew Pheng Lim, Christophe Bodenreider, and Pei-Yong Shi -- Testing antiviral compounds in a dengue mouse model / Wouter Schul, Andy Yip, and Pei-Yong Shi -- Construction of self-replicating subgenomic west nile virus replicons for screening antiviral compounds / Sofia L. Alcaraz-Estrada, Erin Donohue Reichert, and Radhakrishnan Padmanabhan -- Part IV Herpes viruses -- Methods for screening and profiling inhibitors of herpes simplex viruses / Edwin Yunhao Gong -- In vivo evaluation of antiviral efficacy against genital herpes using mouse and guinea pig models / Frances Valencia, Ronald L. Veselenak, and Nigel Bourne -- Fluorescence-based high-throughput screening assay for identifying human cytomegalovirus inhibitors / Christel Van den Eynde ... [et al.] -- Part V Respiratory viruses -- Fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus / Leen Kwanten, Ben De Clerck, and Dirk Roymans -- Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells / Anna Lundin, Tomas Bergström, and Edward Trybala -- Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models / Joke Van den Berg, Leen Kwanten, and Dirk Roymans -- In vivo evaluation of antiviral compounds on respiratory syncytial virus using a juvenile vervet monkey (Chlorocebus pygerythrus) infection model / Lieselot Houspie ... [et al.] -- Methods to determine mechanism of action of anti-influenza inhibitors / Angela Luttick, Stephanie Hamilton, and Simon P. Tucker -- Methods for evaluation of antiviral efficacy against influenza virus infections in animal models / Donald F. Smee and Dale L. Barnard -- Part VI Alphaviruses -- Development of a high-throughput antiviral assay for screening inhibitors of chikungunya virus and generation of drug-resistant mutations in cultured cell / Edwin Yunhao Gong ... [et al.] -- Mouse model of chikungunya virus with utility in antiviral studies / Ashley Dagley and Justin G. Julander.
  • 2009 Springer
    contributors, J. Anderson ... [et al.] ; Hans-Georg Kräusslich, Ralf Bartenschlager, editors.
  • 2012 Springer
    Hans-Georg Joost, editor.
    The volume Appetite Control provides a comprehensive description of the mechanisms controlling food intake, and thereby energy balance, in the mammalian organism. During the last decade, research in this area has produced a remarkable wealth of information and has characterized the function of numerous peptides, transmitters, and receptors in appetite control. Dysfunction of these circuits leads to obesity, a growing health concern. However, the plethora of mechanistic information is in marked contrasts to an almost complete lack of anti-obesity drugs that meet the safety standards required for the chronic therapy of morbid obesity. Consequently, ongoing research aims to identify additional targets and agents for a pharmacological intervention. Thus, the mechanisms of appetite control as well as all agents interfering with its control are of considerable practical interest.The authors of the volume are distinguished scientists who are leading experts in the field, and who have contributed important, original data to our understanding of the mechanisms of appetite control. They have quite different scientific backgrounds and, together, they represent all relevant disciplines. Thereby, the topics are presented from different points of view, not exclusively from that of pharmacology and neuroendocrinology. Thus, the volume addresses all scientists who are interested in the field of obesity research and the pathophysiology of appetite control.
  • 2013 Springer
    Arnab De ; with foreword by Jean Martinez.
    Introduction -- Application of prodrug chemistry to GLP-1 -- Experimental procedures -- Characterization of prodrugs -- Conclusion -- Appendix I. Schematic synthesis of longer acting prodrugs -- Appendix II: Structure of peptides in Table A.1 -- Appendix III: Structure of peptides in table A.2 -- Appendix IV: Structure of peptides in table A.3 -- Appendix V: Structure of peptides in table A.4 Appendix VI: Structure of peptides in table A.5 -- Appendix VII. Structure of peptides in table A.6 -- Appendix VIII: Acylataion of HO-His7, GLP(8-37) -- Appendix IX: A note on nomenclature.
  • 2006
    [edited by] Michael E. Burton, Leslie M. Shaw, Jerome J. Schentag ... [et al.].
    Status: Not Checked OutLane Catalog Record
  • 2014 Springer
    Stephan Schmidt, Hartmut Derendorf, editors.
    This comprehensive volume provides an update on the current state of pharmacometrics in drug development. It consists of nineteen chapters all written by leading scientists from the pharmaceutical industry, regulatory agencies and academia. After an introduction of the basic pharmacokinetic and pharmacodynamic concepts of pharmacometrics in drug development, the book presents numerous examples of specific applications that utilize pharmacometrics with modeling and simulations over a variety of therapeutic areas, including pediatrics, diabetes, obesity, infections, psychiatrics, Alzheimer?s disease, and dermatology, among others. The examples illustrate how results from all phases of drug development can be integrated in a more timely and cost-effective process. Applying pharmacometric decision tools during drug development can allow objective, data-based decision making. At the same time, the process can identify redundant or unnecessary experiments as well as some costly clinical trials that can be avoided. In addition to cost saving by expedited development of successful drug candidates, pharmacometrics has an important economic impact in drug product selection. Unsuccessful drug candidates can be identified early and discontinued without expending efforts required for additional studies and allocating limited resources. Hence, pharmacometric modeling and simulation has become a powerful tool to bring new and better medications to the patient at a faster pace and with greater probability of success.
  • 2013 CRCnetBASE
    Robert S. Matson.
    Omics & microarrays revisited -- The commercial microarrays -- Supports & surface chemistries -- The arraying processes -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays.
  • 2010 CRCnetBASE
    Roger L. Lundblad.
    Introduction to biopharmaceutical conformational analysis : issues and methods -- Comparability of biotechnological/biological products and biological generics -- Application of native electrophoresis for the study of protein conformation -- Affinity chromatography including hydrophobic interaction chromatography in the study of biopolymer conformation -- Size-exclusion chromatography and bimolecular conformation -- Use of analytical ultracentrifugation to study biomolecular conformation -- Use of differential scanning calorimetry to measure conformational change in proteins and other biomacromolecules -- Light scattering and biomacromolecular conformation -- Use of luminescence to measure conformational change in biopharmaceuticals with emphasis on protein and protein drug products -- Near-infrared spectroscopy and macromolecular conformation -- Use of mid-infrared and Fourier transform infrared spectroscopy to study conformation of biomacromolecules -- Use of Raman spectroscopy to evaluate biopharmaceutical conformation -- The use of UV-VIS spectrophotometry for the characterization of biopharmaceutical products -- Use of optical rotatory dispersion and circular dichroism to study therapeutic biomacromolecule conformation -- Use of nuclear magnetic resonance for the characterization of biotherapeutic products -- Use of chemical probes for the study of protein conformation -- Use of hydrogen exchange in the study of biopharmaceutical conformation -- Use of chemical modification for the conformational analysis of biopharmaceuticals -- Use of immunology to characterize biopharmaceutical conformation -- Use of limited proteolysis to study the conformation of proteins of biotechnological interest -- Other technologies for the characterization of conformational change in biopharmaceuticals -- Development of an experimental approach for the study of the conformation of a biological therapeutic product.
  • 2007 Springer
    J. Venitz, W. Sittner, editors.
  • 2014 Springer
    Vsevolod V. Gurevich, editor.
    This volume describes our current understanding of the biological role of visual and non-visual arrestins in different cells and tissues, focusing on the mechanisms of arrestin-mediated regulation of GPCRs and non-receptor signaling proteins in health and disease. The book covers wide range of arrestin functions, emphasizing therapeutic potential of targeting arrestin interactions with individual partners.
  • 2015 Springer
    Chris Peers, Prem Kumar, Christopher Wyatt, Estelle Gauda, Colin A. Nurse, Nanduri Prabhakar, editors.
    Every three years, the International Society for Arterial Chemoreception (ISAC) arranges a Meeting to bring together all of the major International research groups investigating the general topic of oxygen sensing in health and disease, with a prime focus upon systemic level hypoxia and carotid body function. This volume summarises the proceedings of the XIXth meeting of the Society, held in Leeds, UK during the summer of 2014. As such this volume represents a unique collection of state of the art reviews and original, brief research articles covering all aspects of oxygen sensing, ranging from the molecular mechanisms of chemotransduction in oxygen sensing cells such as the carotid body type I cells, to the adverse, reflex cardiovascular outcomes arising from carotid body dysfunction as seen, for example, in heart failure or obstructive sleep apnoea. This volume will be of tremendous interest to basic scientists with an interest in the cellular and molecular biology of oxygen sensing and integrative, whole organism physiologists as well as physicians studying or treating the clinical cardiovascular consequences of carotid body dysfunction.
    Also available: Print – 2015
  • 2013 Springer
    Andrea B. Weir, Margaret Collins, editors.
    Ocular toxicity is routinely assessed in toxicology studies conducted for regulatory purposes. Ocular anatomy and physiology and the assessment of ocular toxicity itself can be challenging to scientists involved in the safety assessment of pharmaceuticals, pesticides and other agents. Anatomical and physiological differences between species can impact the nature of ocular effects observed following intended or unintended exposure of ocular tissues to xenobiotics. Ocular Toxicity in Laboratory Animals provides a concise reference addressing ocular anatomy and physiology across species that will enhance the design and interpretation of toxicology studies conducted for regulatory purposes. The book provides an overview of routine and advanced techniques that are used to assess ocular toxicity including slit lamp biomicroscopy, indirect ophthalmoscopy, electrophysiology and imaging methods for the anterior and posterior segments of the eye. Additionally, the book defines the regulatory expectations for pharmaceuticals intended to treat ocular diseases and for other non-pharmaceutical regulated chemicals. With contributions from experts in the field, Ocular Toxicity in Laboratory Animals is an authoritative, accessible guide for toxicologists and other scientists involved in conducting toxicology studies for regulatory purposes and/or reviewing data from such studies.
  • pts. 1-2, 1974.
    Hippius, Hanns.
    Status: Not Checked OutLane Catalog Record
    pt. 1. Psychopharmacological screening tests. pt. 2. Non-invasive methods in cardiovascular human pharmacology.
  • 2014 Springer
    Chirukandath Gopinath, Vasanthi Mowat.
    "This atlas contains more than 700 illustrations that the authors have collected over the years as well as references and information pertaining to recently developed drug classes, including biologics. It is a useful bench reference for practicing pathologists and may also be used as a reference text by other experts from related fields. The atlas is organised into different chapters based on systemic pathology. Each chapter has illustrations with legends, and the atlas includes some rare examples of unique lesions found during toxicity studies over many years."--Publisher's website.
  • 2008 CRCnetBASE
    edited by Richard G. Wax, Kim Lewis, Abigail A. Salyers, Harry Taber.
    Microbial drug resistance: a historical perspective / William C. Summers -- Ecology of antibiotic resistance genes / Abigail A. Salyers, Nadja Shoemaker, and David Schlesinger -- Global response systems that confer resistance / Paul F. Miller and Philip N. Rather -- Multidrug efflux pumps: structure, mechanism, and inhibition / Olga Lomovskaya ... [et al.] -- Mechanisms of aminoglycoside antibiotic resistance / Gerard D. Wright -- Resistance to [beta]-lactam antibiotics mediated by [beta]-lactamases : structure, mechanism, and evolution / Jooyoung Cha, Lakshmi P. Kotra, and Shahriar Mobashery -- Target modification as a mechanism of antimicrobial resistance / David C. Hooper -- Antibiotic permeability / Harry Taber -- Genetic methods for detecting bacterial resistance genes / Ad C. Fluit -- Evolution and epidemiology of antibiotic-resistant pneumococci / Christopher Gerard Dowson and Krzysztof Trzcinski -- Antimicrobial resistance in the enterococcus / George M. Eliopoulos -- Methicillin resistance in staphylococcus aureus / Keeta S. Gilmore, Michael S. Gilmore, and Daniel F. Sahm -- Mechanism of drug resistance in mycobacterium tuberculosis / Alex S. Pym and Stewart T. Cole -- Antibiotic resistance in enterobacteria / Nafsika H. Georgopapadakou -- Resistance as a worldwide problem / Paul Shears -- Public health responses to antimicrobial resistance in outpatient and inpatient settings / Cindy R. Friedman and Arjun Srinivasan -- Antibacterial drug discovery in the 21st century / Steven J. Projan.
    Also available: Print – 2008
  • 2007 Springer
    M.A. Riley, M.A. Chavan (eds.).
  • 2015 (13th ed.) AccessMedicine
    12th ed., 2012 AccessMedicine
    Katzung, Bertram G.
    Also available: Print – 1982-<2015>
  • 2014 Springer
    Mahdi Balali-Mood, Mohammad Abdollahi, editors.
    This book explains the chemistry of Organophosphorus compounds (OPs), their mechanism of toxicity and the history of OPs from their initial discovery to the development of new compounds such as Novichoks. It details the harmful effects to human health both as a result of acute and chronic OP exposure and the necessary clinical management of affected patients to reduce their toxic side effects. The book also explains the detrimental effect that OPs have had on the environment and the efforts being made to prevent this in the future. Finally, the book looks at the incidents where OPs have been used as chemical warfare agents. Basic and Clinical Toxicology of Organophosphorus Compounds aims to act as a comprehensive guide to all aspects of OPs and is a key resource for clinical toxicologists and related health professionals involved in the prevention, diagnosis and clinical management of OP patients, toxicologists and other scientists involved in research on OPs including regulatory issues and postgraduate students in Toxicology and related fields.
  • 2006
    Janet L. Stringer.
    Status: Not Checked OutLane Catalog Record
    Ch. 1 Where to start -- Ch. 2 Receptor theory -- Ch. 3 Absorption, distribution, and clearance -- Ch. 4 Pharmacokinetics -- Ch. 5 Drug metabolism and renal elimination -- Ch. 6 Review of the autonomic nervous system -- Ch. 7 Cholinergic agonists -- Ch. 8 Cholinergic antagonists -- Ch. 9 Adrenergic agonists -- Ch. 10 Adrenergic antagonists -- Ch. 11 Antihyptertensive drugs -- Ch. 12 Drugs used in ischemic heart disease and congestive heart failure -- Ch. 13 Antiarrhythmic drugs -- Ch. 14. Drugs that affect blood -- Ch. 15 Lipid-lowering drugs -- Ch. 16 Drugs used in Alzheimer's disease -- Ch. 17 Anxiolytic and hypnotic drugs -- Ch. 18 Antidepressants and lithium -- Ch. 19 Antipsychotics or neuroleptics -- Ch. 20 Drugs used in Parkinson's disease -- Ch. 21 Antiepileptic drugs -- Ch. 22 Narcotics (opiates) -- Ch. 23 General anesthetics -- Ch. 24 Local anesthetics -- Ch. 25 Introduction to chemotherapy -- Ch. 26 Inhibitors of cell wall synthesis -- Ch. 26 Inhibitors of cell wall synthesis -- Ch. 27 Protein synthesis inhibitors -- Ch. 28 Folate antagonists -- Ch. 29 Quinolones and urinary tract antiseptics -- Ch. 30 Drugs used in tuberculosis and leprosy -- Ch. 31 Antifungal drugs -- Ch. 32 Anthelmintic drugs -- Ch. 33 Antiviral drugs -- Ch. 34 Antiprotozoal drugs -- Ch. 35 Anticancer drugs -- Ch. 36 Adrenocortical hormones -- Ch. 37 Sex steroids -- Ch. 38 Thyroid and parathyroid drugs -- Ch. 39 Insulin, glucagon, and oral hypoglycemic drugs -- Ch. 40 Histamine and antihistamines -- Ch. 41 Respiratory drugs -- Ch. 42 Drugs that affect the GI tract -- Ch. 43 Nonnarcotic analgesics and anti-inflammatory drugs -- Ch. 44 Immunosuppressives -- Ch. 45 Drugs used in osteoporosis -- Ch. 46 Toxicology and poisoning.
  • 2014 WHO
    "This manual informs about practical procedures in ... assessment based on experience from existing national fluoridation programmes. The assessment tools will primarily be useful in assisting countries in achieving an effective fluoride exposure. It is a hope that the manual will stimulate oral health personnel and public health administrators to use a systematic approach for managing and analysing data obtained from different levels of fluoride exposure. Finally the manual encourages inter-country collaboration on surveillance systems for community programmes using fluoride for prevention of dental caries."--Publisher's description.
    Also available: Print – 2014
  • 2015 Springer
    James Leong, Sam Salek, Stuart Walker ; foreword by Hans-Georg Eichler.
    Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
  • 19??.
    issued by the Scientific Department of the Sandoz Chemical Works.
  • 2014 Wiley
    Blanca Hernandez-Ledesma and Miguel Herrero.
  • 2006 CRCnetBASE
    Scott Patterson, Byron Jones.
  • 2012 Springer Protocols
    edited by Richard S. Larson, the University of New Mexio, Albuqerque, NM, USA.
    Cell perturbation screens for target identification by RNAi / Kubilay Demir and Michael Boutros -- Using functional genomics to identify drug targets : a Dupuytren's disease example / Mirela Sedic, Sandra Kraljevic Pavelic, and Karlo Hock -- Functional characterization of human genes from exon expression and RNA interference results / Dorothea Emig [and others] -- Barcode sequencing for understanding drug-gene interactions / Andrew M. Smith [and others] -- High-throughput sequencing of the methylome using two-base encoding / Christina A. Bormann Chung -- Applications and limitations of in silico models in drug discovery / Ahmet Sacan, Sean Ekins, and Sandhya Kortagere -- Compound Collection Preparation for Virtual screening / Cristian G. Bologa and Tudor I. Oprea -- Mapping between databases of compounds and protein targets / Sorel Muresan, Markus Sitzmann, and Christopher Southan -- Predictive cheminformatics in drug discovery : statistical modeling for analysis of micro-array and gene expression data / N. Sukumar, Michael P. Krein, and Mark J. Embrechts -- Advances in nuclear magnetic resonance for drug discovery / Laurel O. Sillerud and Richard S. Larson -- Human ABC transporter ABCG2 in cancer chemotherapy : drug molecular design to circumvent multidrug resistance / Toshihisa Ishikawa [and others] -- Protein interactions : mapping interactome networks to support drug target discovery and selection / Javier De Las Rivas and Carlos Prieto -- Linking variants from genome-wide association analysis to function via transcriptional network analysis / Benjamin J. Keller, Sebastian Martini, and Viji Nair -- Models of excitation-contraction coupling in cardiac ventricular myocytes / M. Saleet Jafri -- Integration of multiple ubiquitin signals in proteasome regulation / Marta Isasa, Alice Zuin, and Bernat Crosas.
  • 2012 Wiley
    edited by Nathan Brown.
  • 2007 Springer
    W.-H. Boehncke, H.H. Radeke (eds.).
  • 2008 Springer
    edited by Feng Wang.
  • 2008 Springer
    edited by Rajesh Krishna and Lawrence Yu.
  • 2013 Springer
    Jean-Louis Prugnaud, Jean-Hugues Trouvin, editors.
    Biologicals' Characteristics / K. Ho and J.-H. Trouvin -- From the Biosimilar Concept to the Marketing Authorisation / M. Pavlovic and J.-L. Prugnaud -- Immunogenicity / J.-L. Prugnaud -- Substitution and Interchangeability / J.-L. Prugnaud -- G-CSFs: Onco-Hematologist's Point of View / D. Kamioner -- The Oncologist's Point of View / C. Chouaïd -- Biosimilars: Challenges Raised by Biosimilars: Who is Responsible for Cost and Risk Management? / F. Megerlin.
  • 2014 CRCnetBASE
    Shein-Chung Chow.
    "This is the first book entirely devoted to the design and analysis for assessment of biosimilarity and drug interchangeability of biosimilars, and test for comparability in manufacturing processes of biologic products. It covers all of the statistical issues that may occur in biosimilar studies under various study designs at various stages of research and development of biologic products"-- Provided by publisher.
  • 2012 Springer
    Erik Mosekilde, Olga Sosnovtseva, Amin Rostami-Hodjegan, editors.
  • v. 1-2, 1973.
    contributors: A. L. Delaunois ... [et al.].
    Status: Not Checked OutLane Catalog Record
  • 2013 Wiley
    Rodney J.Y. Ho, Milo Gibaldi.
    Introduction to biopharmaceuticals -- Distinctions of biologic versus small molecule platforms in drug development -- Financing biologic drug development -- Application of biotechnology in drug discovery and early development -- Large-scale production of recombinant proteins -- Clinical pharmacology, toxicology, and therapeutic dosage & response -- Clinical evaluation and regulatory approval & enforcement of biopharmaceuticals -- Pharmacoeconomics and drug pricing / Garrison -- Antibodies and derivatives -- Hematopoietic growth and coagulation factors -- Cytokines and interferons -- Hormones -- Enzymes -- Vaccines / Hu, Ho -- Other biopharmaceutical products -- Advances in personalized medicine : pharmacogenetics in drug therapy -- Gene and cell therapy -- Pharmacoeconomics, outcome, and health technology assessment research in drug development -- Summary and future prospects.
  • 2010 ClinicalKey
    [edited by] Lynn Wecker ; with Lynn M. Crespo ... [et al.].
    Also available: Print – 2010
  • 2010 Wiley
    Abraham, Donald J.; Burger, Alfred; Rotella, David P.
    "... provides an established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development. This flagship reference for medicinal chemists and pharmaceutical professions has been thoroughly updated and expanded across 8 volumes to incorporate the entire process of drug development (preclinical testing, clinical trials, etc.) alongside the traditional strengths in medicinal chemistry and drug discovery"--Provided by publisher.
  • 2008 ebrary
    Martin Austin.
    The role of business development -- Planning the portfolio -- Identifying the needs -- Profiling and searching for opportunities -- Modelling and valuation -- Structuring for value -- Due diligence and negotiations -- Sealing the deal : the control -- Making the transaction work.
  • 2007 CRCnetBASE
    edited by Barry D. Smith, Uma Gupta, B.S. Gupta.
  • 2013 Springer
    Tyler J. Curiel, editor.
    This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
  • 2014 Springer
    Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee, editors.
    This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
  • 2014 Springer Protocols
    edited by Ann M. Bode and Zigang Dong.
    Combining computational and experimental methods for identifying molecular targets of phytochemicals / Ann M. Bode and Zigang Dong -- Common methods used for the discovery of natural anticancer compounds / Min Tang ... [et al.] -- Nrf2-target approaches in cancer chemoprevention mediated by dietary phytochemicals / Francisco Fuentes ... [et al.] -- Methods to analyze chemopreventive effect of silibinin on prostate cancer biomarkers protein expression / Gagan Deep, Swetha Inturi, and Rajesh Agarwal -- Approach to the evaluation of berries for cancer prevention with emphasis on esophageal cancer / Gary D. Stoner ... [et al.] -- Use of mouse models for lung cancer chemoprevention studies / Yian Wang ... [et al.] -- Azoxymethane plus dextran sulfate sodium-induced mouse colon cancer model for the study of dietary chemoprevention of inflammation-associated carcinogenesis / Ha-Na Lee, Hye-Won Yum, and Young-Joon Surh -- Use of seahorse extracellular flux analyzer in mechanistic studies of naturally occurring cancer chemopreventive agents / Michelle B. Moura ... [et al.] -- Utilizing RNA-seq to define phytochemical-induced alterations in insulin and IGF-regulated transcriptomes / Heather Beckwith and Douglas Yee -- Ex vivo use of keratinocytes from adult mice to define stem cell activities in cancer research / Rebecca J. Morris ... [et al.] -- Quantitation of acetaldehyde-DNA adducts : biomarkers of alcohol consumption / Silvia Balbo and Stephen S. Hecht -- Imaging tools in discovery and development of phytochemical chemopreventive agents / Marna Ericson -- Designing the chemoprevention trials of tomorrow : applying lessons learned from past definitive trials / Karen Colbert Maresso and Ernest Hawk.
  • 2009 Springer
    Patricia H. Reggio, editor.
  • 2014 Wiley
    [edited by] Vincenzo Di Marzo.
    Looking ahead after 50 years of research on cannabinoids / Raphael Mechoulam -- Cannabinoid receptor intracellular signaling : the long journey from binding sites to biological effects / Lawrence C. Blume, Khalil M. Eldeeb, and Allyn C. Howlett -- Endocannabinoid biochemistry : what do we know after 50 years? / Filomena Fezza and Mauro Maccarrone -- Genetic dissection of the endocannabinoid system and how it changed our knowledge of cannabinoid pharmacology and mammalian physiology / Beat Lutz -- Cannabinoids, endocannabinoids, and stress / Cecilia J. Hillard, Qing-song Liu, XiaoQian Liu, Bin Pan, Christopher J. Roberts, and Leyu Shi -- Cannabinoids and the brain : new hopes for new therapies / Javier Fernández-Ruiz, Mariluz Hernández, and Yolanda García-Movellán -- Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases : focus on tetrahydrocannabinol pharmacology / Paolo Caraceni, Francesca Borrelli, Ferdinando A. Giannone, and Angelo A. Izzo -- Years of cannabinoid research and the need for a new nomenclature / Vincenzo Di Marzo and Luciano De Petrocellis.
  • 2008 Springer
    Attila Köfalvi, editor ; editorial and chapters 1, 9, 14, 22 were proofed by Zsófia Gombár.
  • 2008 ScienceDirect
    edited by Satinder Ahuja, M. llias Jimidar.
    Overview of Capillary Electrophoresis in Pharmaceutical Analysis -- Theoretical Consideration in Performance of Various Modes of CE -- Equipment Considerations for Capillary Electrophoresis -- Method Development for Pharmaceutical Analysis -- Role of CE in Drug Substance and Drug Product Development -- General Considerations to Improve Performance of CE Methods -- Overview of Current Regulatory Guidance -- Qualification of CE Instrumentation -- Robustness Testing of CE Methods -- Validation of Analytical Methods Using Capillary Electrophoresis-- The Need for CE Methods in Pharmacopeial Monographs -- CE in Impurity Profiling of Drugs -- Ion Analysis Using Capillary Electrophoresis -- Role of CE in Biopharmaceutical Development and Quality Control -- Capillary Electrophoresis and Bioanalysis -- CE as an Orthogonal Technique to Chromatography -- Capillary Electrochromatography of Pharmaceuticals -- Coupling CE and Chip-based Devices and Mass Spectrometry.
  • 2014 Springer
    Omar M.E. Abdel-Salam, editor.
    This volume provides an up-to-date account of the achievements pertaining to the application of capsaicin and capsaicin-like molecules in the therapy of various human ailments such as pain, non-allergic rhinitis, obesity, tumors, and gastrointestinal, dermatologic, and urologic disorders. It discusses the basic functions of the capsaicin receptor (TRPV1), its mechanisms of action, and its role in physiological and pathological processes. The text focuses on the most recent progress in the use of capsaicin and capsaicin-like molecules as a therapeutic agent and highlights potential pharmaceutical implications of further TRPV1 research. The chapters are written by noted experts in their fields of endeavor. This book offers both clinicians and researchers valuable resource and reference material on the subject that will stimulate future research.
  • 2003 Wiley
    Chi-Huey Wong (ed.).
    ch. 1. Synthetic methodologies / Chikako Saotome, Osamu Kanie -- ch. 2. Complex carbohydrate synthesis / Makoto Kiso, Hideharu Ishida, Hiromune Ando -- ch. 3. The chemistry of sialic acid / Geert-Jan Boons, Alexei V. Demchenko -- ch. 4. Solid-phase oligosaccharide synthesis / Peter H. Seeberger -- ch. 5. Solution and polymer-supported synthesis of carbohydrates / Shin-Ichiro Nishimura -- ch. 6. Enzymatic synthesis of oligosaccharides / Jianbo Zhang, Jun Shao, Prezemk Kowal, Peng George Wang -- ch. 7. Glycopeptides and glycoproteins : synthetic chemistry and biology / Oliver Seitz -- ch. 8. Synthesis of complex carbohydrates : Everninomicin 13,384-1 / K. C. Nicolaou, Helen J. Mitchell, Scott A. Snyder -- ch. 9. Chemical synthesis of asparagine-linked glycoprotein oligosaccharides : recent examples / Yukishige Ito, Ichiro Matsuo -- ch. 10. Chemistry and biochemistry of asparagine-linked protein glycosylation / Barbara Imperiali, Vincent W.-F. Tai -- ch. 11. Conformational analysis of C-glycosides and related compounds : programming conformational profiles of C- and O-glycosides / Peter G. Goekjian, Alexander Wei, Yoshito Kishi -- ch. 12. Synthetic lipid A antagonists for sepsis treatment / William J. Christ, Lynn D. Hawkins, Michael D. Lewis, Yoshito Kishi -- ch. 13. Polysialic acid vaccines / Harold J. Jennings -- ch. 14. Synthetic carbohydrate-based vaccines / Stacy J. Keding, Samuel J. Danishefsky -- ch. 15. Chemistry, biochemistry, and pharmaceutical potentials of glycosaminoglycans and related saccharides / Tasneem Islam, Robert J. Linhardt -- ch. 16. A new generation of antithrombotics based on synthetic oligosaccharides / Maurice Petitou, Jean-Marc Herbert -- ch. 17. Sequencing of oligosaccharides and glycoproteins / Stuart M. Haslam, Kay-Hooi Khoo, Anne Dell -- ch. 18. Preparation of heterocyclic 2-deoxystreptamine aminoglycoside analogues and characterization of their interaction with RNAs by use of electrospray ionization mass spectrometry / Richard H. Griffey, Steven A. Hofstadler, Eric E. Swayze -- ch. 19. Glycosylation analysis of a recombinant P-selectin antagonist by high-pH anion-exchange chromatography with pulsed electrochemical detection (HPAEC/PED) / Mark R. Hardy, Richard J. Cornell -- ch. 20. Analytical techniques for the characterization and sequencing of glycosaminoglycans / Ram Sasisekharan, Zachary Shriver, Mallik Sundaram, Ganesh Venkataraman -- ch. 21. Thermodynamic models of the multivalency effect / Pavel I. Kitov, David R. Bundle -- ch. 22. Synthetic multivalent carbohydrate ligands as effectors or inhibitors of biological processes / Laura L. Kiessling, Jason K. Pontrello, Michael C. Schuster -- ch. 23. Glycosyltransferase inhibitors / Karl-Heinz Jung, Richard R. Schmidt -- ch. 24. RNA-aminoglycoside interactions / Haim Weizman, Yitzhak Tor -- ch. 25. Glycosylated natural products / Jon S. Thorson, Thomas Vogt -- ch. 26. Novel enzymatic mechanisms in the biosynthesis of unusual sugars / Alexander Wong, Xuemei He, Hung-Wen Liu -- ch. 27. Neoglycolipids : identification of functional carbohydrate epitopes / Ten Feizi, Alexander M. Lawson, Wengang Chai -- ch. 28. A preamble to aglycone reconstruction for membrane-presented glycolipid mimics / Murugesapillai Mylvaganam, Clifford A. Lingwood -- ch. 29. Small molecule inhibitors of the sulfotransferases / Dawn E. Verdugo, Lars C. Pedersen, Carolyn R. Bertozzi -- ch. 30. Carbohydrate-based treatment of cancer metastasis / Reiji Kannagi -- ch. 31. N-acetylneuraminic acid derivatives and mimetics as anti-influenza agents / Robin Thomson, Mark Von Itzstein -- ch. 32. Modified and modifying sugars as a new tool for the development of therapeutic agents : the biochemically engineered N-acyl side chain of sialic acid : biological implications and possible uses in medicine / Rüdiger Horstkorte, Oliver T. Keppler, Werner Reutter -- ch.33 . Modified and modifying sugars as a new tool for the development of therapeutic agents : glycosidated phospholipids as a new type of antiproliferative agents / Kerstin Danker, Annette Fischer, Werner Reutter -- ch. 34. Glycoside primers and inhibitors of glycosylation / Jillian R. Brown, Mark M. Fuster, Jeffrey D. Esko -- ch. 35. Carbohydrate-based drug discovery in the battle against bacterial infections : new opportunities arising from programmable one-pot oligosaccharide synthesis / Thomas K. Ritter, Prof. Dr. Chi-Huey Wong.
  • 19??.
    issued by the Scientific Department of the Sandoz Chemical Works.
  • 2012 Springer
    Isabelle Mercier, Jean-François Jasmin, Michael P. Lisanti, editors.
    1. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression / T.C. Thompson, S.A. Tahir, L. Li, M. Watanabe, K. Naruishi, G. Yang, Ken-ichi Tabata, S. Kurosaka, K. Edamura, R. Tanimoto, P. Corn, D. Kadmon, C.J. Logothetis, P. Troncoso, C. Ren, A. Goltsov, and S. Park -- 2. Caveolin-1 in Colon Cancer: The Flexible Connection to Wnt Signaling / Andrew F.G. Quest, Vicente A. Torres, Diego A. Rodriguez, Jorge Gutierrez-Pajares, and Julio C. Tapia -- 3. Caveolin-1 and Pancreatic Ductal Adenocarcinoma / David W. Rittenhouse, Oeendree Mukherjee, Nathan G. Richards, Charles J. Yeo, Agnieszka K. Witkiewicz, and Jonathan R. Brody -- 4. Caveolin-1 in Brain Tumors / Rebecca Senetta and Paola Cassoni -- 5. The Role of Caveolin-1 in Skin Cancer -- / Alessandra Carè, Isabella Parolini, Federica Felicetti, and Massimo Sargiacomo -- 6. Caveolins in Tumor Angiogenesis / Grzegorz Sowa -- 7. Caveolin-1 and Breast Cancer / Gloria Bonuccelli and Michael P. Lisanti -- 8. Caveolin-1 and Cancer-Associated Stromal Fibroblasts / Isabelle Mercier and Michael P. Lisanti.
  • 2012 Springer
    Malay Chatterjee, Khosrow Kashfi, editors.
    1. GRB2 Signaling as a Molecular Target for Cancer / Alessio Giubellino -- 2. Human Arylamine N-acetyltransferase 1: From Drug Metabolism to Drug Target / Fernando Rodrigues-Lima, Julien Dairou, Florent Busi, and Jean-Marie Dupret -- 3. Targeting Argininosuccinate Synthetase in Cancer Therapy / Niramol Savaraj, Min You, Chunjing Wu, Macus Tien Kuo, Vy Dinh, Medhi Wangpaichitr, and Lynn Feun -- 4. Parathyroid Hormone-Related Peptide Signaling in Cancer / Franco Oreste Ranelletti and Giovanni Monego -- 5. Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma / Francesco Piazza and Gianpietro Semenzato -- 6. Role of Bile Acids in Carcinogenesis of Gastrointestinal Tract / Hiroshi Yasuda and Fumio Itoh -- 7. AIB1: A Transcriptional Coactivator Which Integrates Signaling Cross Talk in Cancer Cells / Macarena Ferrero and Jaime Font de Mora -- 8. Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy / Naijie Jing -- 9. Estrogen Receptor Signaling in Lung Cancer / P.A. Hershberger and J.M. Siegfried -- 10. Microparticle Dissemination of Biological Activities: Implications for Cancer Biology / Pauline P. Goh -- 11. Protein Kinase D Signaling in Cancer / Peter Storz -- 12. Cell Signaling and Cancer: Integrated, Fundamental Approach Involving Electron Transfer, Reactive Oxygen Species, and Antioxidants / Peter Kovacic and Ratnasamy Somanathan -- 13. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy / Fabio P.S. Santos, Inbal Hazan-Halevy, and Zeev Estrov.
  • 2013 Springer
    John Geigert.
    An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).
  • 2013 Springer
    Larry J. Anderson, Barney S. Graham, editors.
    Part I. Virology, pathogenesis, and clinical and epidemiological features of disease -- Part II. Host response to infection and genetics of disease -- Part III. Vaccine platforms and treatment options -- Part IV. Animal and tissue culture models of infection -- Part V. Conclusions -- Index.
  • 2007 NAP
    Leslie Pray and Sally Robinson, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
  • 2006 CRCnetBASE
    David E. Thurston.
    Introduction to cancer -- Antimetabolites -- DNA-interactive agents -- Antitubulin agents -- Cell signaling inhibitors -- Hormonal therapies -- Tumour targeting strategies -- Biologicals -- The future -- Personalized medicine (oncogenomics) -- Adjunct therapies.
  • 2013 CRCnetBASE
    edited by Goutam Brahmachari.
    "Natural products play crucial roles in modern drug development and constitute a prolific source of novel lead compounds or pharmacophores for ongoing drug discovery programs. Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds presents cutting-edge research in the chemistry of bioactive natural products and demonstrates how natural product research continues to make significant contributions in the discovery and development of new medicinal entities."--Page [4] of cover.
  • 2015 Springer
    edited by Philip K. Moore, Matt Whiteman.
    This book puts hydrogen sulfide in context with other gaseous mediators such as nitric oxide and carbon monoxide, reviews the available mechanisms for its biosynthesis and describes its physiological and pathophysiological roles in a wide variety of disease states. Hydrogen sulfide has recently been discovered to be a naturally occurring gaseous mediator in the body. Over a relatively short period of time this evanescent gas has been revealed to play key roles in a range of physiological processes including control of blood vessel caliber and hence blood pressure and in the regulation of nerve function both in the brain and the periphery. Disorders concerning the biosynthesis or activity of hydrogen sulfide may also predispose the body to disease states such as inflammation, cardiovascular and neurological disorders. Interest in this novel gas has been high in recent years and many research groups worldwide have described its individual biological effects. Moreover, medicinal chemists are beginning to synthesize novel organic molecules that release this gas at defined rates with a view to exploiting these new compounds for therapeutic benefit.
  • 2014 Wiley
    edited by Jürgen Bajorath.
  • 2007 Springer
    edited by Jeffrey K. Harrison and Nicholas W. Lukacs.
  • 2009 CRCnetBASE
    Thomas S.C. Li.
    With the addition of 130 herbs and 100 new references, the second edition provides a basic understanding of the science behind Chinese herbal preparations. Using the same format that made the first edition so popular, author Thomas Li provides a seamless integration of topics drawn from a diverse array of sources. The first table presents major constituents and therapeutic values of more than 1800 species. The data are arranged alphabetically by the Latin name followed by common Chinese and English names. Tables 2 and 3 present data on a total of 700 North American herbs belonging to the same species or genus as Chinese herbs, and a comparison of active ingredients and claimed therapeutic values. Appendices 1, 2, and 3 cross-reference Chinese and scientific names, and major active ingredients and their sources in the Chinese and North American herbs cited in the tables.
  • 2013 Springer Protocols
    edited by Gerhard K.E. Scriba.
    Chiral recognition in separation science : an overview / Gerhard K.E. Scriba -- Enantioseparations by thin-layer chromatography / Massimo Del Bubba [and others] -- Gas-chromatographic enantioseparation of unfunctionalized chiral hydrocarbons : an overview / Volker Schurig and Diana Krieidler -- HPLC enantioseparation on cyclodextrin-based chiral stationary phases / Yong Wang and Siu Choon Ng -- Enantioseparations by high-performance liquid chromatography using polysaccharide-based chiral stationary phases : an overview / Bezhan Chankvetadze -- Common screening approaches for efficient analytical method development in LC and SFC on columns packed with immobilized polysaccharide-derived chiral stationary phases / Pilar Franco and Tong Zhang -- Chiral separations by HPLC on immobilized polysaccharide chiral stationary phases / Imran Ali, Zeid A. AL-Othman, and Hassan Y. Aboul-Enein -- Enantioseparations by high-performance liquid chromatography using macrocyclic glycopeptide-based chiral stationary phases : an overview / István Ilisz [and others] -- Enantioseparations of primary amino compounds by high-performance liquid chromatography using chiral crown ether-based chiral stationary phase / Myung Ho Hyun -- Screening of Pirkle-type chiral stationary phases for HPLC enantioseparations / Gregory K. Webster and Ted J. Szczerba -- Enantioseparations by high-performance liquid chromatography based on chiral ligand-exchange / Benedetto Natalini, Roccaldo Sardella, and Federica Ianni -- Enantioseparations by high-performance liquid chromatography using molecularly imprinted polymers / David A. Spivak -- Chiral mobile phase additives in HPLC enantioseparations / Lushan Yu, Shengjia Wang, and Su Zeng -- Chiral benzofurazan-derived derivatization reagents for indirect enantioseparations by HPLC / Toshimasa Toyo'oka -- Separation of racemic 1-(9-Anthryl)-2,2,2-trifluoroethanol by sub-/supercritical fluid chromatography / Xiqin Yang, Leo Hsu, and Gerald Terfloth -- Chiral separations by simulated moving bed method using polysaccharide-based chiral stationary phases / Toshiharu Minoda -- Enantioseparations by capillary electrophoresis using cyclodextrins as chiral selectors / Gerhard K.E. Scriba and Pavel Jáč -- Application of dual cyclodextrin systems in capillary electrophoresis enantioseparations / Anne-Catherine Servais and Marianne Fillet -- Enantioseparations in nonaqueous capillary electrophoresis using charged cyclodextrins / Anne-Catherine Servais and Marianne Fillet -- Use of macrocyclic antibiotics as the chiral selectors in capillary electrophoresis / Chengke Li and Jingwu Kang -- Application of polymeric surfactants in chiral micellar electrokinetic chromatography (CMEKC) and CMEKC coupled to mass spectrometry / Jun He and Shahab A. Shamsi -- Cyclodextrin-modified micellar electrokinetic chromatography for enantioseparations / Wan Aini Wan Ibrahim, Dadan Hermawan, and Mohd Marsin Sanagi -- Cyclodextrin-mediated enantioseparation in microemulsion electrokinetic chromatography / Claudia Borst and Ulrike Holzgrabe -- Chiral separations by capillary electrophoresis using proteins as chiral selectors / Jun Haginaka -- Enantioseparation by chiral ligand-exchange capillary electrophoresis / Yi Chen and Lijuan Song -- Experimental design methodologies in the optimization of chiral CE or CEC separations : an overview / Bieke Dejaegher, Debby Mangelings, and Yvan Vander Heyden -- Chiral capillary electrophoresis-mass spectrometry / Elena Domínguez-Vega, Antonio L. Crego, and Maria Luisa Marina -- Application of chiral ligand-exchange stationary phases in capillary electrochromatography / Martin G. Schmid -- Polysaccharide-derived chiral stationary phases in capillary electrochromatography enantioseparations / Zhenbin Zhang, Hanfa Zou, and Junjie Ou -- Open tubular molecular imprinted phases in chiral capillary electrochromatography / Won Jo Cheong and Song Hee Yang -- Enantioseparations in capillary electrochromatography using sulfated poly [beta]-cyclodextrin-modified silica-based monolith as stationary phase / Ruijuan Yuan and Guosheng Ding -- Cyclodextrin-mediated enantioseparations by capillary electrochromatography / Dorothee Wistuba and Volker Schurig.
  • 2014 CRCnetBASE
    editor, Se-Kwon Kim.
    Part 1. Synthesis and characterization of chitin and chitosan derivatives -- part 2. Biological activities of chitin and chitosan derivatives -- part 3. Biomedical applications of chitin and chitosan derivatives.
  • 2013 Springer
    Achim Kramer, Martha Merrow, editors.
    Molecular and cellular basis of circadian clocks -- Molecular components of the mammalian circadian clock / Ethan D. Buhr and Joseph S. Takahashi -- The epigenetic language of circadian clocks / Saurabh Sahar and Paolo Sassone-Corsi -- Peripheral circadian oscillators in mammals / Steven A. Brown and Abdelhalim Azzi -- Cellular mechanisms of circadian pacemaking: beyond transcriptional loops / John S. O'Neill, Elizabeth S. Maywood, and Michael H. Hastings -- The clock in the brain: neurons, glia, and networks in daily rhythms / Emily Slat, G. Mark Freeman Jr., and Erik D. Herzog -- Circadian control of physiology and behavior -- Circadian clocks and metabolism / Biliana Marcheva, Kathryn M. Ramsey, Clara B. Peek, Alison Affinati, Eleonore Maury, and Joseph Bass -- The circadian control of sleep / Simon P. Fisher, Russell G. Foster, and Stuart N. Peirson -- Daily regulation of hormone profiles / Andries Kalsbeek and Eric Fliers -- Circadian clocks and mood-related behaviors / Urs Albrecht -- Chronopharmacology and chronotherapy -- Molecular clocks in pharmacology / Erik S. Musiek and Garret A. FitzGerald -- Cancer chronotherapeutics: experimental, theoretical,and clinical aspects / E. Ortiz-Tudela, A. Mteyrek, A. Ballesta, P.F. Innominato, and F. Lévi -- Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy / Marina P. Antoch and Roman V. Kondratov -- Light and the human circadian clock / Till Roenneberg, Thomas Kantermann, Myriam Juda, Ceéline Vetter, and Karla V. Allebrandt -- Systems biology of circadian clocks -- Mathematical modeling in chronobiology / G. Bordyugov, P.O. Westermark, A. Korenčič, S. Bernard, and H. Herzel -- Mammalian circadian clock: the roles of transcriptional repression and delay / Yoichi Minami, Koji L. Ode, and Hiroki R. Ueda -- Genome-wide analyses of circadian systems / Akhilesh B. Reddy -- Proteomic approaches in circadian biology / Maria S. Robles and Matthias Mann.
  • 2014 CRCnetBASE
    edited by Claudio Carini, Sandeep Menon, Mark Chang.
    "The successful utilization of biomarkers in clinical development and, indeed, realization of personalized medicine require a close collaboration among different stakeholders: clinicians, biostatisticians, regulators, commercial colleagues, and so on. For this reason, we invited experts from different fields of expertise to address the opportunities and challenges, and discuss recent advancements related to biomarkers and their translation into clinical development. The first four chapters discuss biomarker development from a clinical perspective ranging from introduction to biomarkers to recent advances in RNAi screens, epigenetics, and rare disease as targets for personalized medicine approaches. Chapters 5 through 10 are devoted to considerations from a statistical perspective, and the last chapter addresses the regulatory issues in biomarker utilization. A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as pathological process or response to a therapeutic intervention. Although there is nothing new about biomarkers such as glucose for diabetes and blood pressure for hypertension, the current focus on molecular biomarkers has taken the center stage in the development of molecular medicine. Molecular diagnostic technologies have enabled the discovery of molecular biomarkers and are assisting in the definition of the pathogenic mechanism of diseases. Biomarkers represent the basis of the development of diagnostic assays as well as the target for drug discovery. Biomarkers can help monitoring drugs effect in clinical trials as well as in clinical practice"-- Provided by publisher.
  • 2014 Springer
    Keith A. Foster, editor.
    Currently, there are tremendous advances being made in understanding the basic science of both the structure and function of botulinum neurotoxins. This knowledge is opening up opportunities in regard to both therapeutic uses and treatment and protection options for civil and bio-defense applications. This volume fully evaluates the status of neurotoxin research and exploitation, with a focus on clinical application. The book is a multi-authored collection of chapters written by the leading authorities responsible for the current scientific and clinical research that is advancing the understanding and exploitation of the neurotoxins, and is both up to date and authoritative.
  • 2015 Springer
    Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
    This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
  • 2006 Springer
    edited by S.R. Pandi-Perumal and J.M. Monti.
    Also available: Print – 2006
  • 2012 ClinicalKey
    Peter N. Bennett, Morris J. Brown, Pankaj Sharma.
    A thorough knowledge of pharmacological and therapeutic principles is vital if drugs are to be used safely and effectively for increasingly informed patients. Those who clearly understand how drugs get into the body, how they produce their effects, what happens to them in the body, and how evidence of their therapeutic effect is assessed, will choose drugs more skilfully, and use them more safely and successfully than those who do not. Now in a fully revised 11th edition, Clinical Pharmacology is essential reading for undergraduate medical students, junior doctors and anyone concerned with ev.
  • 2013 Wiley
    Curtis L. Meinert.
  • 2012 Cambridge
    edited by Bernard Ravina, Jeffrey Cummings, Michael McDermott, R. Michael Poole.
    Comprehensive book that suggests ways to improve the efficiency of clinical trials and the development of interventions in the neurosciences.
  • 2009. Karger
    volume editors, K.M. Woodbury-Harris, B.M. Coull.
  • 2015 Wiley
    Laurent Simon and Juan Ospina.
    "Covers the modeling of drug-delivery systems and provides mathematical tools to evaluate and build controlled-release devices"--Provided by publisher.
  • 2009 Springer
    Rafael Gutiérrez, editor.
  • 2015 Springer
    Kathleen M. Kantak, Joseph G. Wettstein, editors.
    "This book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery and presents perspectives on multiple special topics ranging from therapeutic drug use in children, emerging technologies and non-pharmacological approaches to cognitive enhancement."--Publisher's website.
  • 2013 Springer
    Elisabeth Hildt, Andreas G. Franke, editors.
    Medical and Psychosocial Aspects of Cognitive Enhancement -- Pharmacological Neuroenhancement: Substances and Epidemiology / Andreas G. Franke, Klaus Lieb -- Psychopharmacological Neuroenhancement: Evidence on Safety and Efficacy / Dimitris Repantis -- A Bubble of Enthusiasm: How Prevalent Is the Use of Prescription Stimulants for Cognitive Enhancement? / Bradley Partridge -- Modeling the Effects of Modafinil on Selective Attention Electroencephalographic Neural Correlates / Carlos Trenado -- Behavioral Neuroenhancement / Martin Dresler -- The Influence of Sports on Cognitive Task Performance - A Critical Overview / Pavel Dietz -- The Human Experiment: How We Won't Win the Rat Race. What Can We Learn from Brain Stimulation in Humans and Rats About Enhancing the Functional Neurobiology of Higher Cognitive Functions? / Colleen A. Dockery -- Philosophical and Ethical Aspects of Cognitive Enhancement -- Better Brains or Bitter Brains? The Ethics of Neuroenhancement / Kirsten Brukamp -- Cognitive Enhancement - To What End? / Michael Hauskeller -- Nano-bionic Devices for the Purpose of Cognitive Enhancement: Toward a Preliminary Ethical Framework / Frédéric Gilbert -- Cognitive-Enhancing Drugs, Behavioral Training and the Mechanism of Cognitive Enhancement / Emma Peng Chien -- What Is Cognitive Enhancement and Is It Justified to Point Out This Kind of Enhancement Within the Ethical Discussion? / Roland Kipke -- No Pain, No Gain? Objections to the Use of Cognitive Enhancement on the Basis of Its Potential Effects on the Value of Achievement / Lisa Forsberg -- Does the Cognitive Enhancement Debate Call for a Renewal of the Deliberative Role of Bioethics? / Cynthia Forlini, Eric Racine -- Sociological, Political and Legal Aspects of Cognitive Enhancement -- The Biopolitics of Cognitive Enhancement / Peter B. Reiner -- Are We Heading Towards an 'Enhancement Society'? / Armin Grunwald -- Leveling the Playing Field: Fairness in the Cognitive Enhancement Debate / Greta Wagner -- My Mind Is Mine!? Cognitive Liberty as a Legal Concept / Jan-Christoph Bublitz -- Cognitive Enhancement and Criminal Behavior / Elizabeth Shaw -- Enhanced Control and Criminal Responsibility / John Danaher.
  • 2014 Wiley
    edited by Dr. Rathnam Chaguturu, iDDPartners, Princeton Junction, NJ, USA.
    Perspectives on collaborative innovation -- Governmental initiatives accelerate precompetitive collaboration -- A game changer for averting future pharma cliff -- Nonprofits drive bench-to-bedside innovation -- Academic screening centers come of age -- Intellectual property and technology transfer -- The final frontier.
  • 2010 CRCnetBASE
    edited by Monzer Fanun.
    Surfactants and block copolymers in drug delivery / Ambikanandan Misra ... [et al.] -- Application of colloidal properties in drug delivery / Swarnlata Saraf -- Polymeric nanocapsules for drug delivery : an overview / Sílvia S. Guterres ... [et al.] -- Poly(alkyl cyanoacrylate) nanoparticles for drug delivery and vaccine development / Anja Graf, Karen Krauel-Göllner, Thomas Rades -- Stimuli-sensitive polymer gels for dermal and transdermal drug delivery and their application in the development of smart textile materials / Witold Musial and Vanja Kokol -- Micelles : the multifunctional nanocarrier for colloidal drug delivery / Chandana Mohanty, Sarbari Acharya, and Sanjeeb K. Sahoo -- Multiple emulsions : an overview and pharmaceutical applications / Jatin Khurana, Somnath Singh, and Alekha K. Dash -- Pharmaceutical and biotechnological applications of multiple emulsions / Rita Cortesi and Elisabetta Esposito -- Nanoemulsions as drug delivery systems / Figen Tirnaksiz, Seyda Akkus, and Nevin Celebi -- Microemulsion systems : application in delivery of poorly soluble drugs / Ljiljana Djekic and Marija Primorac -- Diclofenac solubilization in mixed nonionic surfactants microemulsions / Monzer Fanun -- Self-emulsifying drug delivery systems / D. P. Maurya, Yasmin Sultana, and M. Abul Kalam -- Liquid crystals and their application in the field of drug delivery / Rakesh Patel and Tanmay N. Patel -- Liquid crystalline nanoparticles as drug nanocarriers / Anan Yaghmur and Michael Rappolt -- Niosomal delivery system for macromolecular drugs / Yongzhuo Huang, Faquan Yu, and Wenquan Liang -- A new class of mesoscopic aggregates as a novel drug delivery system / Federico Bordi, Cesare Cametti, and Simona Sennato -- Liposomes and biomacromolecules : effects of preparation protocol on in vitro activity / Paola Luciani, Debora Berti, and Piero Baglioni -- Colloidal nanocarrier systems as a tool for improving antimycobacterial and antitumor activities and reducing the toxicity of usnic acid / N. S. Santos-Magalhães ... [et al.] -- Dendrimers in drug delivery / Hu Yang -- Microsphere : a novel drug delivery system / Abdus Samad ... [et al.] -- Colloids in aerosol drug delivery system / Nazrul Islam -- Respiratory aerosol dynamics with applications to pharmaceutical drug delivery / Jinxiang Xi, P. Worth Longest, and Paula J. Anderson -- Colloidal carriers for drug delivery in dental tissue engineering / Nader Kalaji, Nida Sheibat-Othman, and Hatem Fessi -- Classification and application of colloidal drug delivery systems : passive or active tumor targeting / H. Yesim Karasulu, Burcak Karaca, and Ercüment Karasulu -- Nanocarriers for imaging applications / Vandana Patravale and Medha Joshi.
  • 2011 Thieme Book
    Heinz Luellmann, Klaus Mohr, Lutz Hein ; illustrator, Juergen Wirth.
  • 2010 Springer
    edited by Iqbal Ahmad, Mohammad Owais, Mohammed Shahid, Farrukh Aqil
    "Presents recent research developments to aid fighting fungal infections The currently available means of combating fungal infections are still weak and clumsy. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. Interestingly, several novel antifungal drug targets have already been identified and validated. However, it is too early to expect any novel antifungal drug as drug discovery programs are still in their infancy. In addition to classical and genomic approaches to drug discovery, traditional knowledge derived from natural products and phytomedicine can provide a multitude of alternative modes of combating fungal infection. This book comprises 20 chapters on various aspects pertaining to fungal diseases in human and animals, their reservoir, fungal pathogenesis, their management and recent advances in their treatment. Issues of antifungal drug toxicity, especially nephrotoxicity, are also discussed. The development of resistance in fungal pathogens, including multidrug resistance and its mechanism, is dealt with in two chapters. Diverse diagnostic approaches to fungal infections are also reviewed. The combinational drug strategies used in combating invasive fungal infections are addressed in detail. The management of pulmonary mycoses in stem cell transplantation is also given special focus. Novel antifungal drugs (synthetic and herbal), fungal vaccines, and metabolic pathways as drug targets are discussed in detail in three different chapters. Subsequently the roles of innate immunity, cytokine therapy and immunomodulators in the treatment of fungal infections are elaborated upon. As novel drug delivery systems have a great potential for modifying the pharmacokinetics of medications, the last chapter takes this fact into consideration in its examination of state-of-the-art delivery systems in controlling fungal infections."--Publisher's website.
  • 2015 Springer
    Maciej Banach, editor.
    Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
  • 2010 Springer
    Fiona Cunningham, Jonathan Elliott, Peter Lees, editors.
    This volume addresses not only a series of key topics in the discipline of veterinary pharmacology and therapeutics that will be of interest to those researching and treating animal disease, but also emphasising the comparative aspects of the subject and the interface with human health and disease.
  • 2012 Wiley
    Zaher A. Radi.
    The first thorough review of cyclooxygenase inhibitors, including their toxicity mechanisms and toxicopathological risks. Cyclooxygenases (COXs) are enzymes responsible for the formation of an important class of biological mediators called prostanoids. Prostanoids such as prostaglandins mediate inflammatory and anaphylactic reactions. For those suffering from inflammation and pain, the pharmacological inhibition of COXs, with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can provide relief. Yet the use of NSAIDs can trigger toxicological effects as well, leading to potential health risks. Comparative Pathophysiology and Toxicology of Cyclooxygenases provides a comprehensive overview of how COX inhibitors affect various bodily systems, specifically the toxicity mechanisms triggered when the COX enzyme is inhibited. The book provides an introduction to the discovery of cyclooxygenases, their use as therapeutic agents, as well as an historical perspective. Shedding light on the differences in expression, pathophysiology, and toxicology of COX inhibitors across species, the book offers a systematic examination of the effects and pathophysiology of COX inhibitors and their mechanisms of toxicity, beginning with the GI tract. Subsequent chapters cover: The pathophysiology of COX inhibition on bone, tendon, and ligament healing, COX inhibitors and renal system pathophysiology and mechanisms of toxicity, The pathophysiologic role of COX inhibition in the ocular system, COX inhibition and the respiratory and cardiovascular systems. The book also sheds light on the latest research devoted to developing COX inhibitors with no adverse side-effects. The first book to offer a thorough comparative look at the toxicological effects of COX inhibitors throughout the body, this invaluable resource will help advance the research and development of safer and more effective COX drugs.
  • 2007 ScienceDirect
    editors-in-chief, John B. Taylor, David J. Triggle.
    v. 1. Global perspective / volume editor, Peter D. Kennewell -- v. 2. Strategy and drug research / volume editor, Walter H. Moos -- v. 3. Drug discovery technologies / volume editor, Hugo Kubinyi -- v. 4. Computer-assisted drug design / volume editor, Jonathan S. Mason -- v. 5. ADME-Tox approaches / volume editors, Bernard Testa and Han van de Waterbeemd -- v. 6. Therapeutics areas I: central nervous system, pain, metabolic syndrome, urology, gastrointestinal and cardiovascular / volume editor, Michael Williams -- v. 7. Therapeutic areas II: cancer, infectious diseases, inflammation & immunology and dermatology / volume editors, Jacob J. Plattner & Manoj C. Desai -- v. 8. Case histories and cumulative subject index / volume editors, John B. Taylor & David J. Triggle.
  • 2013 CRCnetBASE
    edited by Edgar Jacoby.
    This book focuses on applications of compound library design and virtual screening to expand the bioactive chemical space, to target hopping of chemotypes to identify synergies within related drug discovery projects or to repurpose known drugs, to propose mechanism of action of compounds, or to identify off-target effects by cross-reactivity analysis. Both ligand-based and structure-based in silico approaches, as reviewed in this book, play important roles for all these applications. Computational chemogenomics is expected to increase the quality and productivity of drug discovery and lead.
  • 2012 Springer Protocols
    edited by Riccardo Baron.
    A molecular dynamics ensemble-based approach for the mapping of druggable binding sites / Anthony Ivetac and J. Andrew McCammon -- Analysis of protein binding sites by computational solvent mapping / David R. Hall, Dima Kozakov, and Sandor Vajda -- Evolutionary trace for prediction and redesign of protein functional sites / Angela Wilkins [and others] -- Information entropic functions for molecular descriptor profiling / Anne Mai Wassermann [and others] -- Expanding the conformational selection paradigm in protein-ligand docking / Guray Kuzu [and others] -- Flexibility analysis of biomacromolecules with application to computer-aided drug design / Simone Fulle and Holger Gohlke -- On the use of molecular dynamics receptor conformations for virtual screening / Sara E. Nichols, Riccardo Baron, and J. Andrew McCammon -- Virtual ligand screening against comparative protein structure models / Hao Fan, John J. Irwin, and Andrej Sali -- AMMOS software : method and application / Tania Pencheva [and others] -- Rosetta ligand docking with flexible XML protocols / Gordon Lemmon and Jens Meiler -- Normal mode-based approaches in receptor ensemble docking / Claudio N. Cavasotto -- Application of conformational clustering in protein-ligand docking / Giovanni Bottegoni, Walter Rocchia, and Andrea Cavalli -- How to benchmark methods for structure-based virtual screening of large compound libraries / Andrew J. Christofferson and Niu Huang -- AGGRESCAN : method, application, and perspectives for drug design / Natalia S. de Groot [and others] -- ATTRACT and PTOOLS : open source programs for protein-protein docking Sebastian Schneider [and others] -- Prediction of interacting protein residues using sequence and structure data / Vedran Franke, Mile Šikić, and Kristian Vlahoviček -- MM-GB/SA rescoring of docking poses / Cristiano R.W. Guimarães -- A case study of scoring and rescoring in peptide docking / Zunnan Huang and Chung F. Wong -- The solvated interaction energy method for scoring binding affinities / Traian Sulea and Enrico O. Purisima -- Linear interaction energy : method and applications in drug design / Hugo Guitiérrez-de-Terán and Johan Åqvist -- Estimation of conformational entropy in protein-ligand interactions : a computational perspective / Anton A. Polyansky, Ruben Zubac, and Bojan Zagrovic -- Explicit treatment of water molecules in data-driven protein-protein docking : the solvated HADDOCKing approach / Panagiotis L. Kastritis, Aalt D.J. van Dijk, and Alexandre M.J.J. Bonvin -- Protein-water interactions in MD simulations : POPS/POPSCOMP solvent accessibility analysis, solvation forces and hydration sites / Arianna Fornili [and others] -- Computing the thermodynamic contributions of interfacial water / Zheng Li and Themis Lazaridis -- Assignment of protonation states in proteins and ligands : combining pKa prediction with hydrogen bonding network optimization / Elmar Krieger [and others] -- Best practices in free energy calculations for drug design / Michael R. Shirts -- Independent-trajectory thermodynamic integration : a practical guide to protein-drug binding free energy calculations using distributed computing / Morgan Lawrenz [and others] -- Free energy calculations from one-step perturbations / Chris Oostenbrink -- Using metadynamics and path collective variables to study ligand binding and induced conformational transitions / Neva Bešker and Francesco L. Gervasio -- Accelerated molecular dynamics in computational drug design / Jeff Wereszczynski and J. Andrew McCammon -- Molecular dynamics applied in drug discovery : the case of HIV-1 protease / Yi Shang and Carlos Simmerling -- Decomposing the energetic impact of drug-resistant mutations : the example of HIV-1 protease-DRV binding / Yufeng Cai and Celia Schiffer -- Guide to virtual screening : application to the Akt phosphatase PHLPP / William Sinko [and others] -- Molecular-level simulation of pandemic influenza glycoproteins / Rommie E. Amaro and Wilfred W. Li -- Homology modeling of cannabinoid receptors : discovery of cannabinoid analogues for therapeutic use / Chia-en A. Chang [and others] -- High-throughput virtual screening lead to discovery of non-peptidic inhibitors of West Nile virus NS3 protease / Danzhi Huang.
  • 2015 Wiley
    edited by Defang Ouyang and Sean C. Smith.
    Introduction of computational pharmaceutics / Ouyang -- Crystal energy landscapes for aiding crystal form selection / Sarah Price -- Solubilization of poor-soluble drugs in cyclodextron formulation / Ouyang -- Molecular modeling for polymeric and micellar drug delivery / Sharon M.Loverde -- Solid dispersion : a pragmatic method to improve the bioavailability of poorly soluble drugs / Ouyang -- Computer simulations of lipid membranes and liposomes for drug delivery / Becky Notman -- Molecular modeling for protein aggregation and formulation / Jim Warwicker -- Computational simulation of drug delivery by nano-materials at molecular level / Youyong Li -- Molecular and analytical modeling of nanodiamond for drug delivery applications / Amanda Barnard -- Molecular modeling of LDH drug delivery systems / Vinuthaa Murthy -- Molecular dynamics simulation as a tool to study the efficacy of PEGylation / Alex Bunker -- Synchrotron radiation micro computed tomography : a new approach for quantitative 3D structural architecture of drug delivery systems / Jiwen Zhang -- Pharmacokinetic modelling and simulation in drug delivery / Raj.
  • 2008 CRCnetBASE
    Anders Kallen.
    Empirical pharmacokinetics -- Numerical methods for PK parameter estimation -- Physiological aspects on pharmacokinetics -- Modelling the distribution process -- PK/PD modelling.
  • 2013 Wiley
    Laurent Simon.
    Mathematical models -- Linearization and deviation variables -- Stability considerations -- Laplace transforms of linear systems -- Inverse laplace transforms -- Transfer functions -- Dynamic behaviors of typical plants -- Closed-loop responses with P, PI and PID controllers -- Frequency response analysis -- Stability analysis of feedback systems -- Design of feedback controllers -- Feedback control of dead-time systems -- Cascade and feedforward control strategies -- Effective time constant -- Optimal control and design.
  • 19??.
  • 2001- Wiley
    editorial board, S.J. Enna (editor-in-chief) ... [et al.].
  • 2015 Springer Protocols
    edited by Mar Orzáez, Mónica Sancho Medina, Enrique Pérez-Payá.
    Immunoprecipitation of Cdy-Cyclin complexes for determination of kinase activity / Edurne Gallastegui and Oriol Bachs -- Expression and purification of recombinant cyclins and CDKs for activity evaluation / Edurne Gallastegui and Oriol Bachs -- Expression and purification of recombinant CDKs : CDK7, CDK8, and CDK9 / Reena Pinbero and Krassi,ir Yankulov -- Preparation of CDK/Cyclin inhibitor complexes for structural determination / Asterios I. Grigoroudis and George Kontopidis -- Fragment-based De Novo design of cyclin-dependent kinase 2 inhibitors / R Sunil Kumar Tripathi, Poonam Singh, and Sanjeev Kumar Singh -- Protein-protein interaction for the De Novo design of cyclin-dependent kinase peptide inhibitors / Karthiga Arumugasamy [and three others] -- Identification of cylin A bingers with a fluorescent peptide sensor / Elena Pazos, José L. Mascareñas, and Eugenio Vazquez -- Cell synchronization techniques to study the action of CDK inhibitors / Beatriz Pérez-Benavente and Rosa Farrás -- Analysis of CDK inhibitor action on mitochondria-mediated apoptosis / Anna Gortat -- Evaluating the effects of CDK inhibitors is ischemia-reperfusion injury models / Tatiana Guevara -- Assessing cell cycle independent function of the CDK inhibitor p21[superscript]CDKNIA in DNA repair / Ilaria Dutto, Micol Tillhon, and Ennio Properi -- Drug delivery strategies of chemical CDK inhibitors / Daniel Alvira and Laura Mondragon -- Animal models for studying the in vitro functions of cell cycle CDKs / Sanjiv Risal, Deepak Adhikari, and Kui Liu -- Evaluating chemical CDK inhibitors as cell death inducers / Hiroshi Hirai and Yoko Nakatsuru.
  • 2008 Springer Protocols
    edited by Samir S. Ayoub, Roderick J. Flower, Michael P. Seed.
    Part I. In vitro protocols for studying expression and activity of cyclooxygenase enzymes and characterisation of their inhibition patterns -- 1. In vitro cyclo-oxygenase expression and activity protocols : introduction to Part I / Roderick J. Flower -- 2. Techniques used to study regulation of cyclooxygenase-2 promoter sites / Hiroyasu Inoue and Rieko Nakata -- 3. Purification of recombinant human COX-1 and COX-2 / James K. Gierse -- 4. Cloning and expression of cyclooxygenase-1 and cyclooxygenase-2 / Nicholas R. Staten and Beverly A. Reitz -- 5. Expression of cyclooxygenase isoforms in the baculovirus expression system / John C. Hunter, Natalie M. Myres, and Daniel L. Simmons -- 6. Peroxidase active site activity assay / Kelsey C. Duggan, Joel Musee, and Lawrence J. Marnett -- 7. Study of inhibitors of the PGH synthases for which potency Is regulated by the redox state of the enzymes / Olivier Boutaud and John A. Oates -- 8. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors / Stefan Laufer and Sabine Luik -- 9. In vitro cyclooxygenase activity assay in tissue homogenates / Samir S. Ayoub -- 10. Techniques used to characterize the binding of cyclooxygenase Inhibitors to the cyclooxygenase active site / William F. Hood -- 11. In vitro Assays for cyclooxygenase activity and inhibitor characterization / Mark C. Walker and James K. Gierse -- -- Part II. Extraction and measurement of prostanoids and isoprostanes -- 12. Extraction and measurement of prostanoids and isoprostanes : introduction to Part II / Paola Patrignani -- 13. Prostanoid extraction and measurement / Lorenzo Polenzani and Samir S. Ayoub -- 14. Measurement of 8-iso-prostaglandin F2a in biological fluids as a measure of lipid peroxidation / Stefania Tacconelli, Marta L. Capone, and Paola Patrignani -- -- Part III. In vivo models to study involvement of cyclooxygenase products in health and disease -- 15. In vivo models to study cyclooxygenase products in health and disease: introduction to Part III / Derek W. Gilroy, Melanie Stables, and Justine Newson -- 16. Protocols to assess the gastrointestinal side effects resulting from inhibition of Cyclo-Oxygenase isoforms / Brendan J.R. Whittle -- 17. Cyclooxygenase enzymes and their products in the carrageenan-induced pleurisy in rats / Adrian R. Moore, Samir S. Ayoub, and Michael P. Seed -- 18. Iloprost-induced nociception : determination of the site of anti-nociceptive action of cyclooxygenase inhibitors and the Involvement of cyclooxygenase products in central mechanisms of nociception / Samir S. Ayoub and Regina M. Botting.
  • 2010 CRCnetBASE
    William S. Kisaalita.
    "This book is based upon cutting-edge research conducted in the authors lab (Cellular Bioengineering), which over the past decade has developed a number of sophisticated techniques to facilitate use of 3D cell based assays or biosensors. This book uses data from peer-reviewed publications to conclusively justify use of 3D cell cultures in cell-based biosensors (assays) for (HTS). The majority of assays performed in accelerated drug discovery processes are biochemical in nature, but there is a growing demand for live cell-based assays. Unlike biochemical ones, cellular assays are functional approximations of in vivo biological conditions and can provide more biologically relevant information"--Provided by publisher.
  • 2014 Wiley
    edited by Rémy D. Hoffmann, Arnaud Gohier, and Pavel Pospisil.
    Part one. Data sources -- part two. Analysis and enrichment -- part three. Applications to polypharmacology -- part four. system biology approaches.
  • 2012
    Nicholas P. Tatonetti.
    Small molecule drugs continue to be an important part of medical therapy. However, their use is plagued by the onset of unexpected side effects, often seen only in late-stage clinical trials or after release to the market. As a result, there have been a number of high profile drug withdrawals because of side effects. More worrisome, however, are side effects that result from drug-drug interactions (DDIs). It is very difficult to empirically study DDIs before drugs enter the market because of the small samples of co-prescribed drugs in most late stage clinical drug (Phase III) studies. Some DDIs can be predicted based on knowledge of shared pathways of metabolism--such as when two drugs share a metabolizing enzyme and so the effective levels of one or both drugs are affected by saturation of the enzyme. But many DDIs are more idiosyncratic and difficult to predict. The most difficult cases are those in which two drugs produce a synergistic effect not seen with either drug alone. Thus, I created surveillance methods to detect unexpected DDIs, relying on clinical databases--both electronic medical records and spontaneous adverse event reporting systems. Understanding DDIs has an additional benefit for drug discovery. If two drugs have a synergistic effect, they may shed new light on the molecular mechanisms of their action or of the diseases they treat. If we use a model not of "one drug-one target" but of multiple interacting cellular pathways that respond to drugs ("the network is the target"), then we can leverage DDIs for the study of disease. However, to do this we need new ways to probe and understand these pathways, such as studying the unexpected synergies between drugs in observational reporting systems. Thus it would be extremely valuable to have computational methods that link adverse events to molecular events. The emergence of large databases linking drugs, diseases, drug effects, demographics and genes offers a new opportunity to create informatics methods for greater understanding small molecule effects at the clinical and biological level. I describe studies in which I have shown the great power of integrating these databases. In particular, I used the FDA Adverse Events Reporting System (FDA-AERS) to discover a signal for abnormal glucose in patients taking both paroxetine and pravastatin. Paroxetine is a selective serotonin reuptake inhibitor antidepressant. Pravastatin is an HMG CoA reductase inhibitor cholesterol-lowering drug. Neither is typically associated with hyperglycemia. Based on my analysis of the FDA-AERS, I examined patient electronic medical records in three separate hospitals (Stanford, Harvard, Vanderbilt), and demonstrated a striking increase in glucose levels on patients on both drugs, compared to their glucose levels on only one of the drugs. I also showed that mice on these two drugs have increased glucose. I am working with FDA to consider a potential update to the drug labels. Although this discovery illustrates the power of clinical data mining, the databases I used are filled with biases that make their use treacherous. I believe there are many similarly valuable discoveries to be made in these databases. However, only with careful attention to systematic biases can I ensure that the predictions I make are valid. In this thesis I describe methods to address the major informatics challenges to detecting and understanding the effects of taking multiple drugs at once. In particular, I have shown that I can (1) remove the bias introduced by unmeasured confounding variables, (2) improve the detection of drug interactions in cases of low or even non-reporting, (3) link drug effects to genes through chemical informatics methods, and (4) validate new drug effects using novel retrospective and prospective studies. The work forms an infrastructure that is useful to (1) pharmacogenomics scientists wishing to understand drug action at the molecular level, (2) pharmacologists wishing to better understand the effects of drugs singly and in combination, and (3) regulatory agencies wishing to understand the efficacy and safety of drugs and drug-interactions at a population level.
  • 2012 Wiley
    edited by Yiyun Cheng.
    Dendrimer Chemistry: Supramolecular Perspectives and Applications / Charles N Moorefield, Sujith Perera, George R Newkome -- Physicochemical Properties of Dendrimers and Dendrimer Complexes / Toyoko Imae -- The Use of Dendrimers to Optimize the Physicochemical and Therapeutic Properties of Drugs / Nicole Stieger, Wilna Liebenberg, Marique E Aucamp, Melgardt M De Villiers -- Biological Properties of Phosphorus Dendrimers / Anne-Marie Caminade, Jean-Pierre Majoral -- Dendrimer-Based Prodrugs: Synthesis and Biological Evaluation / Mohammad Najlah, Zhengyuan Zhou, Antony D'Emanuele -- Improving the Biocompatibility of Dendrimers in Drug Delivery / Yiwen Li, Libo Zhao, Yiyun Cheng -- Degradable Dendrimers for Drug Delivery / Marc Gingras, Myriam Roy -- Design of Stimuli-Responsive Dendrimers for Biomedical Purposes / Chie Kojima -- Dendrimer-Based Gene Delivery Systems: Administration Routes and Evaluation / M J Santander-Ortega, I F Uchegbu, A G -- Triazine Dendrimers for DNA and siRNA Delivery: Progress, Challenges, and Opportunities / Meredith A Mintzer, Olivia M Merkel, Thomas Kissel, Eric E Simanek -- Dendrimer-Coated Carbohydrate Residues as Drug Delivery Trojan Horses in Glycoscience / Yoann M Chabre, Reň Roy -- Nuclear Magnetic Resonance Techniques in the Analysis of Pamam Dendrimer-Based Drug Delivery Systems / Xueyan Feng, Kun Yang, Jingjing Hu, Tongwen Xu, Yiyun Cheng -- Dendrimer-Based Medical Nanodevices for Magnetic Resonance Imaging Applications / Hongdong Cai, Mingwu Shen, Xiangyang Shi -- Dendrimer-Related Nanoparticle System for Computed Tomography Imaging / Chen Peng, Xiangyang Shi -- Index -- Wiley Series in Drug Discovery and Development.
  • 2005 CRCnetBASE
    edited by Jim E. Riviere.
  • 2015 Springer Protocols
    edited by Gerald Thiel.
    Defining the functional equivalence of wild-type and chemically engineered G protein-coupled receptors / Elisa Alvarez-Curto and Graeme Milligan -- Design and analysis of an arrestin-biased DREADD / Ken-ichiro Nakajima ... [et al.] -- Regulation of gene transcription following stimulation of Gαq-coupled designer receptors / Oliver G. Rössler and Gerald Thiel -- Chemogenetic deconstruction of feeding circuits / Michael Krashes -- Dissecting neuronal circuits involved in olfactory-mediated behaviors / Alexia Nunez-Parra ... [et al ] -- Use of DREADDs (Designer Receptors Exclusively Activated by Designer Receptors) in transgenic mouse behavioral models / Daniela Cassataro and Lucas Sjulson -- Pharmacogenetic dissection of neural mechanisms underlying the regulation of sleep-wakefulness using DREADDs / Michihiro Mieda and Takeshi Sakurai -- DREADD'ed addiction : using designer receptors to delineate neural circuits underlying drug-seeking behaviors / Sunila G. Nair, Denis Smirnov, and John F. Neumaier -- DREADDs in Drosophila melanogaster / Charles D. Nichols and Jaime Becnel.
  • 2008 CRCnetBASE
    Manuchair Ebadi.
    The pharmacokinetic basis of therapeutics -- The pharmacodynamic basis of therapeutics -- Adverse reactions and drug-drug interactions -- Herb-drug interactions -- Food-drug interactions.
  • 2006 NAP
    Committee on Clinical Trial Registries, Board on Health Sciences Policy.
  • 2012 Springer
    Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, editors.
    1. Translational Strategies for Development of Antibody-Based Therapeutics: An Overview / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp -- 2. Discovery Process for Antibody-Based Therapeutics / Heather H. Shih -- 3. Technologies for the Generation of Human Antibodies / Ramesh R. Bhatt, John S. Haurum and C. Geoffrey Davis -- 4. Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics / Randall J. Brezski and Juan Carlos Almagro -- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics / Andrew W. Drake and Giuseppe A. Papalia -- 6. Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics / Mohammad Tabrizi -- 7. Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Immunogenicity / Cherryl B. Funelas and Scott L. Klakamp -- 8. Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology / Gregory Landes and Kathleen Elias -- 9. Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology / David C. Blakey -- 10. Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics / Lolke de Haan -- 11. Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics / Donald E. Mager -- 12. Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics / Feng Jin -- 13. Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics / Mohammad A. Tabrizi and Cherryl B. Funelas -- 14. Translational Research in Alzheimer's Disease for Development of Antibody-Based Therapeutics / Eric C. Yuen, Enchi Liu and Gene G. Kinney -- 15. Considerations in Manufacturing Process Development for Antibody-Based Therapeutics / Paula C. Miller and Peiling Xu -- 16. Strategies for Development of Next Generation Antibody-Based Therapeutics / Mohammad Tabrizi and Gadi Gazit Bornstein -- 17. Immune Complex Therapies for Treatment of Immune Thrombocytopenia / Rong Deng and Joseph P. Balthasar -- 18. Application of Bioinformatics Principles for Target Evaluation / Anthony Carvalloza, Mohammad Fallahi and Sahba Tabrizifard -- 19. Concluding Remarks / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp.
  • 2014 Springer
    Ronald Gieschke, Daniel Serafin.
    The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens?
  • 2012 Springer
    Alexander von Gabain, Christoph Klade, editors.
    Development of novel vaccines gives an overview of the tasks in basic research leading to the final product â" the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page
TO INSTALL, RIGHT CLICK this button.

What is it?

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.

Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.

MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed Plus is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.

Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.

Includes cited reference searching, citation maps, and an analyze tool.

Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.

Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.

Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.

Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.

In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.

A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.

A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.

Over 10,000 notes outline the status of specific infections within each country.

Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.

Provides online, full-text access to Springer's journal titles as well as journals from other publishers.

Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.

Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.
CONTACT US